Document:

Exhibit 4.4

 

 

ESSA PHARMA INC.

 

NOTICE OF

ANNUAL GENERAL AND SPECIAL MEETING

OF SHAREHOLDERS OF

ESSA PHARMA INC.

TO BE HELD ON MAY 21, 2015

 

MANAGEMENT INFORMATION CIRCULAR

 

DATED: APRIL 21, 2015

 

     

     

    

 

ESSA PHARMA INC.

 

Suite 720, 999 West Broadway

Vancouver, British Columbia

Canada V5Z 1K5

 

NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING
OF SHAREHOLDERS

 

NOTICE IS HEREBY GIVEN that the
annual general and special meeting (the “Meeting”) of the shareholders of ESSA Pharma Inc. (the “Company”
or “ESSA”) will be held in the Tudor Room, Rosewood Hotel Georgia, 801 West Georgia St., Vancouver, British
Columbia, V6C 1P7, on May 21, 2015 at 1:30 p.m. (Vancouver time) for the following purposes:

 

		1.	to receive and consider the audited financial statements of the Company for the year ended September
30, 2014 together with the auditor’s report thereon;

 

		2.	to set the number of directors for the ensuing year at six;

 

		3.	to elect directors for the ensuing year;

 

		4.	to appoint an auditor for the ensuing year and authorize the directors to approve the remuneration
to be paid to the auditor;

 

		5.	to consider, and if thought fit, approve with or without amendment, a resolution to approve the
amendment and restatement of the Company’s stock option plan as set out in Schedule A to this Management Information Circular,
as more particularly described herein; and

 

		6.	to transact such other business as may properly come before the meeting.

 

The board of directors has fixed April
21, 2015 as the record date for determining the shareholders entitled to receive notice of and vote at the Meeting. Shareholders
unable to attend the meeting in person are requested to read the enclosed management information circular and proxy (or Voting
Instruction Form, a “VIF”) and complete and deposit the proxy or VIF in accordance with its instructions. Unregistered
shareholders must deliver their complete proxy or VIF in accordance with the instructions given by their financial institution
or other intermediary that forwarded the proxy to them.

 

DATED at Vancouver, British Columbia this 21st
day of April, 2015.

 

	 	ON BEHALF OF THE BOARD OF DIRECTORS
	 	 
	 	Signed: “Robert W. Rieder”
	 	Robert W. Rieder
	 	President, Chief Executive Officer and Director

 

These securityholder materials are being
sent to both registered and non-registered owners of the securities. If you are a non-registered owner, and the issuer or its agent
has sent these materials directly to you, your name and address and information about your holdings of securities, have been obtained
in accordance with applicable securities regulatory requirements from the intermediary holding on your behalf. By choosing to send
these materials to you directly, the Company (and not the intermediary holding on your behalf) has assumed responsibility for (i)
delivering these materials to you, and (ii) executing your proper voting instructions. Please return your voting instructions as
specified in the request for voting instructions.

 

     

     

    

 

ESSA PHARMA INC.

 

Suite 720, 999 West Broadway

Vancouver, British Columbia

Canada V5Z 1K5

 

MANAGEMENT INFORMATION CIRCULAR

as at April
21, 2015

 

This Management Information Circular
is furnished in connection with the solicitation of proxies by the management of ESSA Pharma Inc. (the “Company” or
“ESSA”) for use at the annual general and special meeting (the “Meeting”) of its shareholders to be held
on May 21, 2015 at the time and place and for the purposes set forth in the accompanying notice of the Meeting.

 

In this Management Information Circular,
references to the “Company”, “ESSA”, “we” and “our”
refer to ESSA Pharma Inc. “Common Shares” means common shares without par value in the capital of the Company.
“Beneficial Shareholders” means shareholders who do not hold Common Shares in their own name and “intermediaries”
refers to brokers, investment firms, clearing houses and similar entities that own securities on behalf of Beneficial Shareholders.

 

GENERAL PROXY INFORMATION

 

Solicitation of Proxies

 

The solicitation of proxies will be primarily
by mail, but proxies may be solicited personally or by telephone by directors, executive officers and regular employees of the
Company. The Company will bear all costs of this solicitation. We have arranged for intermediaries to forward the meeting materials
to beneficial owners of Common Shares held as of record by those intermediaries and we may reimburse the intermediaries for their
reasonable fees and disbursements in that regard.

 

Appointment of Proxyholders

 

The individuals named in the accompanying
form of proxy (the “Proxy”) are executive officers and/or directors of the Company. If you are a shareholder
entitled to vote at the Meeting, you have the right to appoint a person or company other than either of the persons designated
in the Proxy, who need not be a shareholder, to attend and act for you on your behalf at the Meeting. You may do so either by inserting
the name of that other person in the blank space provided in the Proxy or by completing and delivering another suitable form of
proxy.

 

Voting by Proxyholder

 

The persons named in the Proxy will vote
or withhold from voting the Common Shares represented thereby in accordance with your instructions on any ballot that may be called
for. If you specify a choice with respect to any matter to be acted upon, your Common Shares will be voted accordingly. The Proxy
confers discretionary authority on persons named therein with respect to:

 

		(a)	each matter or group of matters identified therein for which a choice is not specified, other than
the appointment of an auditor and the election of directors;

 

		(b)	any amendment to or variation of any matter identified therein; and

 

    - 2 -

     

    

 

		(c)	any other matter that properly comes before the Meeting.

 

In respect of a matter for which a choice
is not specified in the Proxy, the management appointee acting as a proxyholder will vote in favour of each matter identified on
the Proxy and, if applicable, for the nominees of management for directors and auditors as identified in the Proxy.

 

Registered Shareholders

 

Registered shareholders may wish to vote
by proxy whether or not they are able to attend the Meeting in person. Registered shareholders electing to submit a proxy may do
so by:

 

		(a)	completing, dating and signing the enclosed form of proxy and returning it to the Company’s
transfer agent, Computershare Trust Company of Canada (“Computershare”), by fax within North America at 1-866-249-7775,
outside North America at (416) 263-9524, or by mail to the 8th Floor, 100 University Avenue, Toronto, Ontario, M5J 2Y1 or by hand
delivery at 2nd Floor, 510 Burrard Street, Vancouver, British Columbia, V6C 3B9;

 

		(b)	using a touch-tone phone to transmit voting choices to a toll free number. Registered shareholders
must follow the instructions of the voice response system and refer to the enclosed proxy form for the toll free number, the holder’s
account number and the proxy access number; or

 

		(c)	logging on to the internet through Computershare’s website at www.investorvote.com.
Registered shareholders must follow the instructions that appear on the screen and refer to the enclosed proxy form for the holder’s
account number and the proxy access number;

 

in all cases ensuring that the proxy is
received at least 48 hours (excluding Saturdays, Sundays and holidays) before the Meeting or the adjournment thereof at which the
proxy is to be used.

 

Beneficial Shareholders

 

The following information is of significant
importance to shareholders who do not hold Common Shares in their own name. Beneficial Shareholders should note that the only
proxies that can be recognized and acted upon at the Meeting are those deposited by registered shareholders (those whose
names appear on the records of the Company as the registered holders of Common Shares) or as set out in the following disclosure.

 

If Common Shares are listed in an account
statement provided to a shareholder by a broker, then in almost all cases those Common Shares will not be registered in the shareholder’s
name on the records of the Company. Such Common Shares will more likely be registered under the names of intermediaries. In Canada,
the vast majority of such Common Shares are registered under the name of CDS & Co. (the registration name for The Canadian
Depository for Securities Limited, which acts as nominee for many Canadian brokerage firms).

 

Intermediaries are required to seek voting
instructions from Beneficial Shareholders in advance of meetings of shareholders. Every intermediary has its own mailing procedures
and provides its own return instructions to clients.

 

There are two kinds of Beneficial
Shareholders - those who object to their name being made known to the issuers of securities which they own (called
“OBOs” for Objecting Beneficial Owners) and those who do not object to the issuers of the securities they
own knowing who they are (called “NOBOs” for Non-Objecting Beneficial Owners).

 

    - 3 -

     

    

 

The Company is taking advantage of the
provisions of National Instrument 54-101 Communication with Beneficial Owners of Securities of a Reporting Issuer that
permit it to deliver proxy-related materials directly to its NOBOs. As a result NOBOs can expect to receive a scannable
Voting Instruction Form (“VIF”) from our transfer agent, Computershare. The VIF is to be completed and returned
to Computershare as set out in the instructions provided on the VIF. Computershare will tabulate the results of the VIFs received
from NOBOs and will provide appropriate instructions at the Meeting with respect to the shares represented by the VIFs they receive.

 

These securityholder materials are being
sent to both registered and non-registered owners of the securities of the Company. If you are a non-registered owner, and the
Company or its agent has sent these materials directly to you, your name, address and information about your holdings of securities,
were obtained in accordance with applicable securities regulatory requirements from the intermediary holding securities on your
behalf.

 

By choosing to send these materials to
you directly, the Company (and not the intermediary holding securities on your behalf) has assumed responsibility for (i) delivering
these materials to you, and (ii) executing your proper voting instructions. Please return your VIF as specified in the request
for voting instructions that was sent to you.

 

Beneficial Shareholders who are OBOs should
follow the instructions of their intermediary carefully to ensure that their Common Shares are voted at the Meeting.

 

The form of proxy supplied to you by your
broker will be similar to the proxy provided to registered shareholders by the Company. However, its purpose is limited to instructing
the intermediary on how to vote your Common Shares on your behalf. Most brokers delegate responsibility for obtaining instructions
from clients to Broadridge Financial Solutions, Inc. (“Broadridge”) in the United States and in Canada. Broadridge
mails a VIF in lieu of a proxy provided by the Company. The VIF will name the same persons as the Company’s Proxy to represent
your Common Shares at the Meeting. You have the right to appoint a person (who need not be a Beneficial Shareholder of the Company),
other than any of the persons designated in the VIF, to represent your Common Shares at the Meeting and that person may be you.
To exercise this right, insert the name of the desired representative (which may be you) in the blank space provided in the VIF.
The completed VIF must then be returned to Broadridge by mail or facsimile or given to Broadridge by phone or over the internet,
in accordance with Broadridge’s instructions. Broadridge then tabulates the results of all instructions received and provides
appropriate instructions respecting the voting of Common Shares to be represented at the Meeting and the appointment of any shareholder’s
representative. If you receive a VIF from Broadridge, the VIF must be completed and returned to Broadridge, in accordance
with its instructions, well in advance of the Meeting in order to have your Common Shares voted or to have an alternate representative
duly appointed to attend the Meeting and vote your Common Shares at the Meeting.

 

Notice to Shareholders in the United States

 

The solicitation
of proxies and the matters to be voted on, as contemplated in this Management Information Circular, involve securities of an
issuer located in Canada and are being effected in accordance with the corporate laws of the Province of British Columbia,
Canada and securities laws of the provinces of Canada. As a “foreign private issuer” as defined under Rule 3b-4
under the United States Securities Exchange Act of 1934, as amended (the “1934 Act”), the
proxy solicitation rules under the 1934 Act, including Regulation 14A thereunder, are not applicable to the Company or
this solicitation, and this solicitation has been prepared in accordance with the disclosure requirements of the securities
laws of the provinces of Canada. Shareholders should be aware that disclosure requirements under the securities laws of the
provinces of Canada differ from the disclosure requirements under United States securities laws.

 

    - 4 -

     

    

 

 

The enforcement by Shareholders of civil
liabilities under United States federal securities laws may be affected adversely by the fact that the Company is incorporated
under the Business Corporations Act (British Columbia), as amended, certain of its directors and its executive officers
are residents of Canada and a substantial portion of its assets and the assets of such persons are located outside the United States.
Shareholders may not be able to sue a foreign company or its executive officers or directors in a foreign court for violations
of United States federal securities laws. It may be difficult to compel a foreign company and its executive officers and directors
to subject themselves to a judgment by a United States court.

 

Revocation of Proxies

 

In addition to revocation in any other
manner permitted by law, a registered shareholder who has given a proxy may revoke it by:

 

		(a)	executing a proxy bearing a later date or by executing a valid notice of revocation, either of
the foregoing to be executed by the registered shareholder or the registered shareholder’s authorized attorney in writing,
or, if the registered shareholder is a corporation, under its corporate seal by an officer or attorney duly authorized, and by
delivering the proxy bearing a later date to Computershare Trust Company of Canada or at the address of the registered office of
the Company at 595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, British Columbia V7X 1L3, at any
time up to and including the last business day that precedes the day of the Meeting or, if the Meeting is adjourned, the last business
day that precedes any reconvening thereof, or to the chairman of the Meeting on the day of the Meeting or any reconvening thereof,
or in any other manner provided by law; or

 

		(b)	personally attending the Meeting and voting the registered shareholder’s Common Shares.

 

A revocation of a proxy will not affect a matter on which a
vote is taken before the revocation.

 

INTEREST OF CERTAIN PERSONS OR COMPANIES IN MATTERS
TO BE ACTED UPON

 

Except as disclosed herein, no director
or executive officer of the Company, nor any person who has held such a position since the beginning of the last completed financial
year end of the Company, nor any proposed nominee for election as a director of the Company, nor any associate or affiliate of
the foregoing persons, has any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise,
in matters to be acted on at the meeting other than the election of directors and appointment of auditors.

 

VOTING SECURITIES AND PRINCIPAL HOLDERS OF VOTING
SECURITIES

 

The board of directors (the “Board”)
of the Company has fixed April 21, 2015 as the record date (the “Record Date”) for determination of persons
entitled to receive notice of the Meeting. Only shareholders of record at the close of business on the Record Date who either attend
the Meeting personally or complete, sign and deliver a form of proxy in the manner and subject to the provisions described above
will be entitled to vote or to have their Common Shares voted at the Meeting.

 

    - 5 -

     

    

 

The Common Shares of the Company are listed
for trading on the TSX Venture Exchange (the “TSXV”). As of the Record Date, there were 18,144,322 Common Shares
issued and outstanding, each carrying the right to one vote.

 

No group of shareholders has the right
to elect a specified number of directors, nor are there cumulative or similar voting rights attached to the Common Shares.

 

To the knowledge of the directors and executive
officers of the Company, the only persons or corporations that beneficially owned, directly or indirectly, or exercised control
or direction over, Common Shares carrying more than 10% of the voting rights attached to all outstanding Common Shares of the Company
as at the Record Date were:

 

	Shareholder Name	Number of Shares Held	Percentage of Issued Shares
	 	 	 
	Marianne Sadar	3,175,000	17.50%
	 	 	 
	Raymond Anderson	3,175,000	17.50%
	 	 	 
	Robert W. Rieder	2,531,250	13.95%

 

FINANCIAL STATEMENTS

 

The audited financial statements of the
Company for the year ended September 30, 2014, report of the auditor and related management discussion and analysis, all of which
may be obtained from SEDAR at www.sedar.com, will be placed before the Meeting and have been filed with the securities commissions
or similar regulatory authority in British Columbia, Alberta and Ontario.

 

VOTES NECESSARY TO PASS RESOLUTIONS

 

A simple majority of affirmative votes
cast at the Meeting is required to pass the resolutions described herein. If there are more nominees for election as directors
or appointment of the Company’s auditor than there are vacancies to fill, those nominees receiving the greatest number of
votes will be elected or appointed, as the case may be, until all such vacancies have been filled. If the number of nominees for
election or appointment is equal to the number of vacancies to be filled all such nominees will be declared elected or appointed
by acclamation.

 

PARTICULARS OF MATTERS TO BE ACTED UPON

 

		1.	Setting the Number of Directors – See heading “Election of Directors”.

 

		2.	Election of Directors – See heading “Election of Directors”.

 

		3.	Appointment of Auditor – See heading “Appointment of Auditor”.

 

		4.	Amendment and Restatement of Stock Option Plan - See heading "Amendment and Restatement
of Stock Option Plan". 

 

ELECTION OF DIRECTORS

 

The Articles
of the Company set out that the number of directors of the Company will be a minimum of three and a maximum of the most recently
set of (i) the number of directors set by ordinary resolution and (ii) the number of directors set in the event that the places
of any retiring directors are not filled by an election at a meeting of shareholders. The term of office of each of the
six current directors will end at the conclusion of the Meeting. Unless the director’s office is vacated earlier in accordance
with provisions of the Business Corporations Act (British Columbia), each director elected will hold office until the conclusion
of the next annual meeting of the Company, or if no director is then elected, until a successor is elected.

 

    - 6 -

     

    

 

Nominees

 

The following table sets out the
names of management’s six nominees for election as directors, all major offices and positions with the Company each now holds,
each nominee’s principal occupation, business or employment, the period of time during which each has been a director of
the Company and the number of Common Shares of the Company beneficially owned by each, directly or indirectly, or over which each
exercised control or direction, as at April 21, 2015:

 

	 	 	 	 	Period as a	 	Common Shares	 
	Name, Country of	 		 	Director of	 	Beneficially	 
	Residence and	 	Principal Occupation or Business or	 	the	 	Owned or	 
	Position	 	Employment(1)	 	Company	 	Controlled(1)	 
	Robert W. Rieder	 	President, Chief Executive Officer and Director,	 	Since	 	 	2,531,250	(3)
	British Columbia,	 	ESSA Pharma Inc. (October 11, 2010-Present)	 	October	 	 	 	 
	Canada	 	Executive Chairman of the Board, Cardiome	 	2010	 	 	 	 
	Chief Executive	 	Pharma Corp. (2009-2010)	 	 	 	 	 	 
	Officer and Director	 	Chief Executive Officer, Cardiome Pharma	 	 	 	 	 	 
	 	 	Corp. (1998-2009)	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Richard M.	 	Chairman of the Board, ESSA Pharma Inc.	 	Since	 	 	845,000	(4)
	Glickman(2)(8)	 	(October 2010-Present)	 	October	 	 	 	 
	British Columbia,	 	Co-founder and Executive Chairman	 	2010	 	 	 	 
	Canada	 	(September 2013-February 2014) and Chairman	 	 	 	 	 	 
	 	 	of the Board (February 2014-Present) Aurinia	 	 	 	 	 	 
	Chairman of the	 	Pharmaceuticals Inc.	 	 	 	 	 	 
	Board	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Marianne Sadar	 	Director (January 6, 2009-Present), Chief	 	Since	 	 	3,175,000	(5)
	British Columbia,	 	Scientific Officer (October 11, 2010-Present)	 	January	 	 	 	 
	Canada	 	and President (January 6, 2009-October 11,	 	2009	 	 	 	 
	 	 	2010), ESSA Pharma Inc.	 	 	 	 	 	 
	Chief Scientific	 	Distinguished Scientist (2012-Present) and	 	 	 	 	 	 
	Officer and Director	 	Senior Scientist (1998-2012), British Columbia	 	 	 	 	 	 
	 	 	Cancer Agency Professor (2012-Present)	 	 	 	 	 	 
	 	 	Honorary Associate Professor (2009-2012),	 	 	 	 	 	 
	 	 	Pathology and Laboratory Medicine, University	 	 	 	 	 	 
	 	 	of British Columbia, Provincial Program	 	 	 	 	 	 
	 	 	Leader for Prostate Cancer Research (2000-	 	 	 	 	 	 
	 	 	2012), British Columbia Cancer Agency	 	 	 	 	 	 
	 	 	Officer (2007-Present), Past President (2014-	 	 	 	 	 	 
	 	 	Present), President (2013-2014), Vice President	 	 	 	 	 	 
	 	 	(2012-2013), and Treasurer (2007-2011),	 	 	 	 	 	 
	 	 	Society of Basic Urologic Research	 	 	 	 	 	 

 

    - 7 -

     

    

 

	 	 	 	 	Period as a	 	Common Shares	 
	Name, Country of	 	 	 	Director of	 	Beneficially	 
	Residence and	 	Principal Occupation or Business or	 	the	 	Owned or	 
	Position	 	Employment(1)	 	Company	 	Controlled(1)	 
	Raymond Andersen	 	Chief Technical Officer and Director (October	 	Since	 	 	3,175,000	(6)
	British Columbia,	 	11, 2010-Present) and Secretary (January 6,	 	October	 	 	 	 
	Canada	 	2009-Present), ESSA Pharma Inc.	 	2010	 	 	 	 
	 	 	Professor of Chemistry and Earth, Ocean &	 	 	 	 	 	 
	Chief Technical	 	Atmospheric Sciences, University of British	 	 	 	 	 	 
	Officer and Director	 	Columbia (2007-present)	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Gary Sollis(2)(8)	 	Director, ESSA Pharma Inc. (April 26, 2012-	 	Since April	 	 	0	(7)
	British Columbia,	 	Present)	 	2012	 	 	 	 
	Canada	 	Partner, Dentons Canada LLP (May 1, 1995-	 	 	 	 	 	 
	 	 	Present)	 	 	 	 	 	 
	Director	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Franklin M.	 	Director, ESSA Pharma Inc. (March 2015-	 	Since	 	 	0	(9)
	Berger(2)(8)	 	Present)	 	March 2015	 	 	 	 
	New York, United	 	Director, Five Prime Therapeutics, Inc.	 	 	 	 	 	 
	States of America	 	(October 2010-Present)	 	 	 	 	 	 
	 	 	Director, Immune Design Corp. (March 2014-	 	 	 	 	 	 
	Director	 	Present)	 	 	 	 	 	 
	 	 	Director, Bellus Health, Inc. (May 2010-	 	 	 	 	 	 
	 	 	Present)	 	 	 	 	 	 
	 	 	Director, Seattle Genetics, Inc. (2003-May	 	 	 	 	 	 
	 	 	2014)	 	 	 	 	 	 

 

Notes:

 

		(1)	The information as to principal occupation, business or employment (for the preceding five years
for any new director) and Common Shares beneficially owned or controlled is not within the knowledge of the management of the Company
and has been furnished by the respective nominees themselves.

 

		(2)	Member of the Audit Committee (as defined herein).

 

		(3)	Of the 2,531,250 Common Shares over which Robert W. Rieder exercises control, 31,250 are held in
the name of his spouse. Robert W. Rieder holds Options to purchase 150,000 Common Shares.

 

		(4)	Of the 845,000 Common Shares over which Richard M. Glickman exercises control, 100,000 are held
in the name of his spouse. Richard M. Glickman holds Options to purchase 75,000 Common Shares.

 

		(5)	Marianne Sadar holds Options to purchase 420,000 Common Shares.

 

		(6)	Raymond Andersen holds Options to purchase 420,000 Common Shares.

 

		(7)	Gary Sollis holds Options to purchase 120,000 Common Shares.

 

		(8)	Member of the Compensation Committee (as defined herein).

 

		(9)	Franklin Berger holds Options to purchase 50,000 Common Shares and special warrants exercisable
for 363,636 Common Shares.

 

None of the proposed nominees for election
as a director of the Company are proposed for election pursuant to any arrangement or understanding between the nominee and any
other person, except the directors and senior officers of the Company acting solely in such capacity.

 

    - 8 -

     

    

 

Director Biographies

 

Robert W. Rieder, President, Chief Executive Officer and
Director

 

Mr. Rieder, 68, has
served as a director of the Company and has been employed full time as the President and Chief Executive Officer of the Company
since October 2010. He is responsible for the management of the Company, developing objectives, strategy and standards of performance,
securing and leading a team of professionals and directing them to deliver the required performance. From 1998 to 2009, Mr. Rieder
was the Chief Executive Officer of Cardiome Pharma Corp. (“Cardiome”), a Toronto Stock Exchange and NASDAQ-traded
public pharmaceutical company. Under Mr. Rieder’s leadership, Cardiome negotiated partnerships with two leading pharmaceutical
companies, Merck Frosst & Co. and Astellas Pharmaceuticals, and raised over $250 million from public capital markets. Mr. Rieder
led Cardiome from the pre-clinical research stage to NDA submission. Mr. Rieder also has an extensive background in medically-related
venture capital investing, as Vice President of MDS Ventures Pacific Inc., a Vancouver-based affiliate of MDS Capital Corp. He
has been a director for nine public and private technology companies. In 2009, he was acknowledged as “Executive of the Year”
by Life Sciences B.C. and in 2007 was named Ernst and Young “Entrepreneur of the Year” for the Medical Products area
in the Pacific Region. He currently is the non-executive Chairman of the Board for Cardiome and is a director of XORTX Pharma Corp.
and B.C. Advantage Funds (VCC) Ltd. Mr. Rieder received his undergraduate degree in Chemical Engineering from the University of
British Columbia and his Master of Business Administration from the Richard Ivey School of Business at the University of Western
Ontario.

 

Richard M. Glickman, Chairman of the Board

 

Chairman of the Board Dr. Richard M. Glickman,
57, has served as the Chairman of the Board of the Company since October 2010. As the Chairman of the Board, Dr. Glickman is responsible
for the management of the Board to ensure the Company has appropriate objectives and an effective strategy, and that it is operating
in accordance with a high standard of corporate governance. Dr. Glickman was a cofounder, Chairman and Chief Executive Officer
of Aspreva Pharmaceuticals Inc. (“Aspreva”) which was acquired by the Galenica group for $915M. Prior to establishing
Aspreva, Dr. Glickman was the co-founder and Chief Executive Officer of StressGen Biotechnologies Corporation. Dr. Glickman currently
serves on Cardiome Pharma Corp.’s Board of Directors as a member of the Compensation and Audit Committees and as its lead
independent director. In addition, Dr. Glickman serves as Chairman of the Board of Aurinia Pharmaceuticals Inc., as Chairman of
the Board of Engene Corporation and as a Director of Vida Pharmaceuticals. In addition, he has served on numerous biotechnology
boards including roles as Chairman of Life Sciences B.C. (formerly the British Columbia Biotechnology Alliance), as a Director
of the Canadian Genetic Diseases Network (a Canadian Centre of Excellence), a member of the federal government’s National
Biotechnology Advisory Committee, a member of the British Columbia Innovation Council and a director for the Vancouver Aquarium
and Chair of its Research Committee. Dr. Glickman received the Ernst & Young Entrepreneur of the Year 2004 Award for the Pacific
Region Life Sciences Group, both Canada’s and British Columbia’s Top 40 under 40 Award for Entrepreneurs, the 2006
BC Biotech Leadership Award and the Lupus Foundation of America Leadership Award.

 

    - 9 -

     

    

 

Marianne Sadar, Chief Scientific Officer and Director

 

Dr. Marianne Sadar,
52, is one of the co-founders of ESSA. Dr. Sadar has been a director of the Company since January 2009, and has acted as the Chief
Scientific Officer of the Company since October 2010. She is responsible for participating in the research and development of ESSA’s
drug candidates, and with the assessment and review of business and scientific matters. As an independent consultant, she devotes
approximately 20% of her time to the affairs of the Company. She is a Distinguished Scientist at the BC Cancer Agency and a Professor
of Pathology and Laboratory Medicine at UBC. Dr. Sadar is internationally known for her research on identifying mechanisms of activating
the AR and developing therapeutics for advanced prostate cancer that target the N-terminal domain of the AR. Her research was the
first to show that the N-terminal domain of the AR could be activated by alternative pathways and she proposed this domain as
a therapeutic target in 1999. Later, Dr. Sadar provided the first proof-of-concept that targeting the N-terminus of the AR results
in a therapeutic response in an in vivo model of CRPC. Dr. Sadar received her B.Sc. from Simon Fraser University, and Ph.D. from
the University of Bradford, U.K. She carried out post-doctoral training at AstraZeneca (Astra Hässle), Department of Drug
Metabolism and Pharmacokinetics in Mölndal, Sweden and at the BC Cancer Agency. She has served on approximately 50 scientific
panels, and has been a recipient of awards including the Terry Fox Young Investigator Award, Simon Fraser University Alumni Award
for Academic Excellence, and the first non-American to receive the Society of Women in Urology/Society of Basic Urologic Research
“Award for Excellence in Urologic Research”. She has served as President of the Society of Basic Urologic Research
(USA), member of the Scientific Advisor Boards for the Prostate Cancer Foundation (USA) and Coalition to Cure Prostate Cancer (Canada).
The Congressionally Directed Medical Research Programs Prostate Cancer Research Program (“ PCRP”) of U.S. Department
of Defense recently named Dr. Sadar to the PCRP Integration Panel. Dr. Sadar’s consulting agreement contains non-competition
and confidentiality clauses.

 

Raymond Andersen, Chief Technical Officer, Secretary and
Director

 

Dr. Raymond Andersen,
67, is one of the co-founders of ESSA. He has served as the Secretary of the Company since January 2009, and as a director and
Chief Technical Officer of the Company since October 2010. He is responsible for participating in the research and development
of ESSA’s drug candidates, and with the assessment and review of business and scientific matters. As an independent consultant,
he devotes approximately 20% of his time to the affairs of the Company. He is also a Professor at UBC in the departments of Chemistry
and Earth & Ocean Sciences. He is internationally known for his research into the identity and structure of novel chemical
compounds derived from marine organisms, the molecular routes to their biosynthesis, their role in ocean ecology, and their potential
as new drugs. Among them are compounds that have anti-inflammatory and anti-cancer properties and these compounds are being developed
as anti-asthma, and anti-tumour drugs. His discoveries represented core technologies of the UBC spinoff companies Aquinox Pharmaceuticals
Inc. and Inflazyme Pharmaceuticals. His industrial programs have led to deals with Aventis and Wyeth and the venture capital arms
of Johnson & Johnson and Pfizer. Dr. Andersen received his B.Sc. degree from the University of Alberta, a M.Sc. from UC Berkeley,
and Ph.D. from U.C. San Diego. He carried out postdoctoral research at the Massachusetts Institute of Technology. In recognition
of his pioneering achievements, Dr. Andersen was inducted into the Royal Society of Canada and recently received the R. U. Lemieux
Award from the Canadian Society for Chemistry and the Jacob Biely Research Prize from UBC. Dr. Andersen’s consulting agreement
contains non-competition and confidentiality clauses.

 

Gary Sollis, Director

 

Mr. Gary Sollis, 61, has served as a
director of the Company since April 2012. Mr. Sollis is a partner at the law firm of Dentons Canada LLP. He represents
clients in the areas of corporate and securities law, with a focus on acquisitions, financings and reorganizations. He has
acted for a variety of public and private companies in financing transactions, including public offerings, private placements
of debt and equity, special warrant financings and public and private limited partnership offerings. Mr. Sollis has also
assisted clients in connection with takeover bids, mergers, proxy contests, spin-offs, joint ventures and acquisitions of
private businesses. He received a Bachelor of Laws degree from Dalhousie University.

 

    - 10 -

     

    

 

Franklin M. Berger, Director

 

Mr. Franklin M. Berger, 65, has served
as a director of the Company since March 2015. He started his consulting practice in 2003 after leaving J. P. Morgan Securities,
Inc. as their head of biotechnology equity research. His clients are exclusively biotechnology industry participants including
major biopharmaceutical firms, mid-capitalization biotechnology companies, specialist asset managers and venture capital companies.
He currently serves on the board of three public biotechnology companies: Five Prime Therapeutics, Inc., Immune Design Corp. and
Bellus Health, Inc. Previous public company board service included 11 years with Seattle Genetics, Inc., seven years with VaxGen,
Inc. (vaccines/biodefense) and Aurinia (previously Isotechnika), based in Canada. He also serves or has served on private biotech
company boards including iTherX Pharma, Inc., Caprion Proteomics (sold in July 2012), Inc. and ViroChem Pharma, Inc. As a senior
portfolio manager on the buy-side, Mr. Berger worked at Sectoral Asset Management as a founder of the small-cap focused NEMO
Fund from 2007 through June 2008. Mr. Berger spent 12 years in sell-side equity research, most recently as Managing Director,
U.S. Equity Research, J. P. Morgan Securities, Inc., from May 1998 to March 2003.

 

Institutional Investor Magazine ranked
him on J. P. Morgan’s All-Star Research Team. The Wall Street Journal selected Mr. Berger as the No. 1 ranked biotechnology
analyst in its All-Star Analyst Survey in 1997 and No. 2 ranked in the WSJ’s 2000 Survey. In 2000, he became a Founding Fellow
of the Biotechnology Study Center at New York University School of Medicine. Mr. Berger received his MBA degree from Harvard Business
School in 1975. Johns Hopkins University conferred both his MA and BA degrees in 1971 and 1972, respectively.

 

Cease Trade Orders and Bankruptcies

 

Except as disclosed below, no proposed
director of the Company is, as of the date of this Management Information Circular, or has been, within the ten years prior to
the date hereof, a director or chief executive officer or chief financial officer of any company (including the Company) that:
(i) was subject to an order that was issued while the proposed director was acting as a director, chief executive officer or chief
financial officer; or (ii) was subject to an order that was issued after the proposed director ceased to be a director, chief executive
officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity
as director, chief executive officer or chief financial officer.

 

Mr. Rieder was a director of Akela Pharma,
Inc. (“Akela”). Due to the late filing of its financial statements, management’s discussion and analysis
and annual information form for the year ended December 31, 2009, Akela applied to the British Columbia Securities Commission for
a management cease trade order, which applied to Mr. Rieder, as well as the rest of Akela’s management. The management cease
trade order was granted on April 6, 2010 and revoked on June 29, 2010 following the filing of all required records. The management
cease trade order did not affect trading in the securities of Akela generally.

 

No proposed
director of the Company is, at the date of this Management Information Circular, or has been within ten years before the date of
this Management Information Circular, a director or executive officer of any company (including the Company) that, while that person
was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal
under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement
or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets.

 

    - 11 -

     

    

 

Penalties and Sanctions

 

No proposed director of the Company has
been subject to any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory
authority or has entered into a settlement agreement with a securities regulatory authority, or has been subject to any other penalties
or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable securityholder in
deciding whether to vote for a proposed director.

 

Individual Bankruptcies

 

No proposed director of the Company has,
within the ten years before the date of this Management Information Circular, become bankrupt, made a proposal under any legislation
relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors,
or had a receiver, receiver manager or trustee appointed to hold the assets of the proposed director.

 

APPOINTMENT OF AUDITOR

 

Davidson & Company LLP, at its offices
located at 1200 – 609 Granville Street, P.O. Box 10372, Pacific Centre, Vancouver, British Columbia, Canada V7Y 1G6, will
be nominated at the Meeting for reappointment as auditor of the Company at remuneration to be fixed by the directors. Davidson
& Company LLP was first appointed as the company’s auditor on May 28, 2013.

 

To be approved, the resolution must be
passed by a majority of the votes cast by the holders of Common Shares at the Meeting. Management recommends a vote “for”
in respect of the resolution approving the appointment of the auditor and authorizing the directors to fix the auditor’s
remuneration.

 

AUDIT COMMITTEE AND RELATIONSHIP WITH AUDITOR

 

National Instrument 52-110 Audit Committees
(“NI 52-110”) requires the Company, as a venture issuer, to disclose annually in its Management Information
Circular certain information concerning the constitution of its audit committee (the “Audit Committee”) and
its relationship with its independent auditor. Such disclosure is set forth below:

 

Audit Committee

 

On September 4, 2014, the Company formed
the Company’s Audit Committee. The Audit Committee is comprised of Richard Glickman, Gary Sollis and Franklin Berger (Chair),
all of whom are “financially literate” as defined in National Instrument 52-110 – Audit Committees (“NI
52-110 ”). Each member of the Audit Committee is considered independent pursuant to NI 52-110. A description of the education
and experience of each Audit Committee member that is relevant to the performance of his responsibilities as an Audit Committee
member may be found above under the heading “Director Biographies”.

 

The Audit
Committee is responsible for reviewing the Company’s financial reporting procedures, internal controls and the performance
of the financial management and the Auditor. The Audit Committee also reviews the annual audited financial statements and makes
recommendations to the board. The Company is relying on the exemption set out in section 6.1 of NI 52-110, which allows the Company
to be exempt from the requirement that all members of the Audit Committee be independent. A copy of the Audit Committee’s
charter is set out below.

 

    - 12 -

     

    

 

Audit Committee Charter

 

		I.	Purpose

 

The main objective of the Audit Committee
is to act as a liaison between the Board and the Company’s independent auditor and to assist the Board in fulfilling its
oversight responsibilities with respect to the financial statements and other financial information provided by the Company to
its shareholders and others.

 

		II.	Organization

 

The Committee shall consist of three or
more directors and shall satisfy the laws governing the Company and the independence, financial literacy, expertise and experience
requirements under applicable securities law, stock exchange requests and any other regulatory requirements applicable to the Audit
Committee of the Company.

 

The members of the Committee and the Chair
of the Committee shall be appointed by the Board. A majority of the members of the Committee shall constitute a quorum. A majority
of the members of the Committee shall be empowered to act on behalf of the Committee. Matters decided by the Committee shall be
decided by majority votes.

 

Any member of the Committee may be removed
or replaced at any time by the Board and shall cease to be a member of the Committee as soon as such member ceases to be a director.

 

The Committee may form and delegate authority to subcommittees
when appropriate.

 

		III.	Meetings

 

The Committee shall meet as frequently as circumstances require.

 

The Committee may invite, from time to
time, such persons as it may see fit to attend its meetings and to take part in discussion and consideration of the affairs of
the Committee.

 

		IV.	Responsibilities

 

 (1) The Committee shall recommend to the Board:

 

 (a) the external auditor to be nominated for the purpose of preparing or issuing an auditor’s report or performing other audit, review or attest services for the Company; and

 

 (b) the compensation of the external auditor.

 

 (2) The Committee shall be directly responsible for overseeing the work of the external auditor engaged for the purpose of preparing or issuing an auditor’s report or performing other audit, review or attest services for the Company, including the resolution of disagreements between management and the external auditor regarding financial reporting.

 

 (3) The Committee must pre-approve all non-audit services to be provided to the Company or its subsidiary entities by the Company’s external auditor.

 

    - 13 -

     

    

 

(4) The Committee must review the
Company’s financial statements, MD&A and annual and interim earnings press releases before the Company publicly
discloses this information.

 

(5) The Committee must be satisfied
that adequate procedures are in place for the review of the Company’s public disclosure of financial information extracted
or derived from the Company’s financial statements, other than the public disclosure referred to in subsection (4), and must
periodically assess the adequacy of those procedures.

 

 (6) The Committee must establish procedures for:

 

(a) the receipt, retention
and treatment of complaints received by the Company regarding accounting, internal accounting controls, or auditing matters; and

 

(b) the confidential,
anonymous submission by employees of the Company of concerns regarding questionable accounting or auditing matters.

 

		V.	Authority

 

The Committee shall have the following authority:

 

(a) to engage independent
counsel and other advisors as it determines necessary to carry out its duties,

 

(b) to set and pay the compensation
for any auditor or tax advisors employed by the Committee, and

 

 (c) to communicate directly with the external auditor.

 

Relevant Education and Experience

 

See heading “Director Biographies”
above for a description of the education and experience of each of the members of the Audit Committee that is relevant to their
performance as an audit committee member, in particular, any education or experience that would provide the member with:

 

		(i)	an understanding of the accounting principles used by the issuer to prepare its financial statements,
and the ability to assess the general application of those principles in connection with estimates, accruals and reserves;

 

		(ii)	experience preparing, auditing, analyzing or evaluating financial statements that present a breadth
and level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably
be expected to be raised by the issuer’s financial statements, or experience actively supervising individuals engaged in
such activities; and

 

		(iii)	an understanding of internal controls and procedures for financial reporting.

 

Audit Committee Oversight

 

Since the commencement of the Company’s
most recently completed financial year, there has not been a recommendation of the Audit Committee to nominate or compensate an
external auditor which was not adopted by the Company’s Board.

 

    - 14 -

     

    

 

Reliance on Certain Exemptions

 

Since the effective date of NI 52-110,
the Company has not relied on the exemptions contained in section 2.4 or Part 8 of NI 52-110. Section 2.4 provides an exemption
from the requirements that the Audit Committee must pre-approve all non-audit services to be provided by the auditor, where the
total amount of fees related to the non-audit services are not expected to exceed 5% of the total fees payable to the auditor in
the fiscal year in which the non-audit services were provided. Section 8 permits a company to apply to a securities regulatory
authority for an exemption from the requirements of NI 52-110, in whole or in part.

 

Pre-Approval Policies and Procedures

 

See the Audit Committee Charter above for
specific policies and procedures for the engagement of non-audit services.

 

Exemption

 

The Company is relying upon the exemption
in section 6.1 of NI 52-110 in respect of its reporting obligations under NI 52-110 for the year ended September 30, 2014.

 

External Auditor Service Fees

 

Fees incurred with Davidson & Company
LLP for audit services in the last two fiscal years for audit fees are outlined in the following table:

 

	 	 	Fees Paid to Auditor in Year Ended	 	Fees Paid to Auditor in Year Ended
	Nature of Services	 	September 30, 2014	 	September 30, 2013
	 	 	 	 	 
	Audit Fees(1)	 	$	32,000.00	 	 	$	15,000	 
	 	 	 	 	 	 	 	 	 
	Audit-Related Fees(2)	 	 	Nil	 	 	 	Nil	 
	 	 	 	 	 	 	 	 	 
	Tax Fees(3)	 	 	Nil	 	 	 	Nil	 
	 	 	 	 	 	 	 	 	 
	All Other Fees(4)	 	 	Nil	 	 	 	Nil	 
	 	 	 	 	 	 	 	 	 
	Total	 	$	32,000.00	 	 	$	15,000	 

 

Notes: 

 

		(1)	“Audit Fees” include fees necessary to perform the annual audit of the Company’s
consolidated financial statements. Audit Fees include fees for review of tax provisions and for accounting consultations on matters
reflected in the financial statements. Audit Fees also include audit or other attest services required by legislation or regulation,
such as comfort letters, consents, reviews of securities filings and statutory audits.

 

		(2)	“Audit-Related Fees” include services that are traditionally performed by the auditor.
These audit-related services include employee benefit audits, due diligence assistance, accounting consultations on proposed transactions,
internal control reviews and audit or attest services not required by legislation or regulation.

 

		(3)	“Tax Fees” include fees for all tax services other than those included in “Audit
Fees” and “Audit-Related Fees”. This category includes fees for tax compliance, tax planning and tax advice.
Tax planning and tax advice includes assistance with tax audits and appeals, tax advice related to mergers and acquisitions, and
requests for rulings or technical advice from tax authorities.

 

    - 15 -

     

    

 

	

 

		(4)	“All Other Fees” include all other non-audit services.

 

AMENDMENT AND RESTATEMENT OF STOCK OPTION PLAN

 

At the Meeting, shareholders will be asked
to approve an ordinary resolution set forth below (the “Option Plan Amendment Resolution”) approving
the amendment and restatement of the Company’s existing stock option plan (the “Option Plan”) governing
the Company’s options to purchase Common Shares (the “Options”). For reference, a copy of the Option Plan
incorporating all proposed amendments is appended hereto as Schedule A (the “Amended and Restated Option Plan”).

 

The existing Option Plan was adopted to
offer incentives to directors, executive officers, employees, management and others who provide services to the Company or any
subsidiary, to act in the best interests of the Company. Prior to September 4, 2014, ESSA did not have in place a formal stock
option plan. Options were issued by the Board on a case-by-case basis, reflecting the priorities in place at each such time point.
On September 4, 2014, ESSA adopted the Option Plan. For a detailed description of the provisions of the Option Plan, please see
“Securities Authorized for Issuance under Equity Compensation Plans - Equity Compensation Plan Information”
below.

 

At the Meeting, shareholders will be asked
to approve the amendment and restatement of the Option Plan and, as a result, the adoption of the Amended and Restated Option Plan.
While based on the Option Plan, the Amended and Restated Option Plan contains certain amendments and also incorporates several
other provisions.

 

Proposed Amendments

 

The existing Option Plan was drafted to
suit the needs of a private issuer, while also containing specified provisions designed to comply with the requirements of the
TSXV (the “TSXV Provisions”) that would become effective upon the Common Shares becoming listed on the TSXV.
When the Common Shares became listed on the TSXV on January 27, 2014, the TSXV Provisions became effective and superseded a number
of provisions drafted to suit the needs of a private issuer. Therefore, in the Amended and Restated Option Plan, all of the provisions
in the existing Option Plan drafted to suit the needs of a private issuer that have been superseded by the TSXV Provisions will
be replaced with the TSXV Provisions. These changes will not have a substantive impact because the provisions that will be removed
have been superseded by the TSXV Provisions.

 

Aside from the changes to replace the provisions
that have been superseded with the TSXV Provisions, the provisions of the Amended and Restated Option Plan will be substantially
similar to those contained in the Option Plan aside from the changes noted below.

 

The Company may in the future apply to
graduate the listing of its Common Shares from the TSXV to the Toronto Stock Exchange (the “TSX”). If the Company
does graduate the listing of its Common Shares to the TSX, the Amended and Restated Plan contains several provisions which will
become effective upon the listing of the Common Shares on the TSX (the “TSX Provisions”). The TSX Provisions,
if the Common Shares become listed on the TSX, will cause the following principal changes to the Amended and Restated Option Plan:

 

		(a)	Amend the provisions relating to the number of Common Shares issuable such that:

 

		a.	the maximum number of Common Shares that may be reserved and available for issuance upon exercise
of Options will be the greater of:

 

    - 16 -

     

    

	

 

		i.	3,614,014 Common Shares; and

 

		ii.	a rolling number equal to 15% of the total issued and outstanding Common Shares from time to time,
subject to a maximum of 5,000,000 Common Shares;

 

		b.	the maximum number of Common Shares that may be reserved and available for issuance under subsection
(a)(ii) above will be increased quarterly at the end of each fiscal quarter of the Company beginning with the fiscal quarter beginning
on April 1, 2015, by an amount equal to the number of Common Shares issued upon exercise of any Options during such fiscal quarter,
provided that the total number of Common Shares reserved and available for issuance does not exceed 15% of the issued and outstanding
Common Shares of the Company; and

 

		c.	any Common Shares subject to an Option that expires or terminates without having been fully exercised
may be made the subject of a further Option.

 

		(b)	Align the defined terms with the definitions provided in the TSX Company Manual as opposed to the
TSXV policies;

 

		(c)	Align the definition of “Insider” and the eligibility and restrictions governing the
granting of Options to such persons to the provisions in the TSX Company Manual as opposed to the TSXV policies;

 

		(d)	Align the exercise price provisions such that the exercise price of an Option cannot be less than
the “Market Price” as defined in the TSX Company Manual;

 

		(e)	Align the amendment provisions such that the amendment provisions are more characteristic of TSX
listed issuer as opposed to a TSXV listed issuer; and

 

		(f)	Provide a net settlement alternative (to replace the cashless exercise alternative which will be
removed from the Option Plan) which will provide that, in lieu of exercising an Option by delivery of an exercise notice along
with payment of the exercise price, any Option holder may elect to transfer and dispose of a specified number of Options to the
Company in exchange for a number of Common Shares having a fair market value equal to the intrinsic value of such Options disposed
of and transferred to the Company.

 

TSX Provisions

 

The Option Plan provides that the maximum
number of Common Shares that will be available for Directors, Officers, Employees and Consultants to acquire pursuant to Options
is 3,614,014 Common Shares, representing 20% of the Company’s issued and outstanding Common Shares as of the date of listing
of the Common Shares on the TSXV. Under the Amended and Restated Option Plan, if the Common Shares become listed on the TSX, the
maximum number of Common Shares that may be reserved and available for issuance upon exercise of Options will be the greater of
(i) the current maximum of 3,614,014 Common Shares; and (ii) a rolling number equal to 15% of the total issued and outstanding
Common Shares from time to time, subject to a maximum of 5,000,000 Common Shares. There are currently 18,144,322 Common Shares
outstanding (15% of which is 2,721,648), therefore, the maximum of 3,614,014 Common Shares would be applicable upon the
listing of the Common Shares on the TSX unless additional Common Shares are issued prior to the listing of the Common Shares on
the TSX.

 

    - 17 -

     

    

 

The TSX Provisions contain a replenishment
feature whereby the maximum number of Common Shares that may be reserved and available for issuance upon exercise of Options will
be increased quarterly at the end of each fiscal quarter of the Company beginning with the fiscal quarter beginning on April 1,
2015 by an amount equal to the number of Common Shares issued upon exercise of any Options during such fiscal quarter, provided
that the total number of Common Shares reserved and available for issuance does not exceed 15% of the issued and outstanding Common
Shares of the Company.

 

The exercise price for Options issued under
the TSX Provisions will be set by the Board; however, the exercise price of an Option cannot be less than the Market Price (as
defined therein) at the time of such grant of Options. The Market Price is defined as the volume weighted average trading price
of the Common Shares, calculated by dividing the total value by the total volume of securities traded for the five trading days
immediately preceding the exercise date.

 

The TSX Provisions provide that the maximum
number of Common Shares issuable cannot exceed the “Insider Participation Limit”, which means the number of Common
Shares: (i) issued to Insiders (as defined in the TSX Company Manual) within any one year period, and (ii) issuable to Insiders
at any time, under the Amended and Restated Option Plan, or when combined with all of the Company’s other security based
compensation arrangements, cannot exceed 10% of the Company’s total issued and outstanding Common Shares, respectively.

 

The TSX Provisions also provide that the
Board will, subject to the requirements of the TSX Company Manual, have the right at any time and from time to time, to amend any
of the provisions of the Amended and Restated Option Plan without consent or approval from shareholders, including without limitation:

 

		(a)	to amend, modify or terminate the Amended and Restated Option Plan with respect to all Common Shares
in respect of Options which have not yet been granted thereunder;

 

		(b)	to make any amendment of a typographical, grammatical, clerical or administrative nature or clarification
correcting or rectifying any ambiguity, immaterial inconsistency, defective provision, mistake, or error or omission;

 

		(c)	to change the provisions relating to the manner of exercise of Options, including changing or adding
any form of financial assistance provided by the Company, or adding or amending provisions relating to a cashless exercise of Options
which provisions so added or amended provide for a full deduction of the underlying common shares of the Company from the maximum
number reserved for issuance under the Amended and Restated Option Plan;

 

		(d)	to change the terms, conditions and mechanics of grant, vesting, exercise and early expiry of Options,
provided that no such change may extend an outstanding Option’s expiry date;

 

		(e)	to change the provisions for termination or cancellation of Options or to extend an outstanding
Option’s expiry date; and

 

		(f)	to make any addition to, deletion from or alteration of the provisions of the Amended and Restated
Option Plan or any Option that are necessary to comply with applicable law or the requirements of any regulatory or governmental
agency or applicable stock exchange and to avoid unanticipated consequences deemed by the board of directors to be inconsistent
with the purpose of the Amended and Restated Option Plan.

 

    - 18 -

     

    

 

The above amendment provisions are also
subject to, among other things, the following restricted amendment provisions which will require Disinterested Shareholder Approval
(as such term is defined in the TSX Company Manual):

 

		(a)	any reduction in the exercise price of an Option previously granted to an Insider subject to limited
exceptions;

 

		(b)	any extension of the expiry date of an Option previously granted to an Insider;

 

		(c)	any amendment to remove or to exceed the Insider Participation Limit;

 

		(d)	any increase in the maximum number of securities issuable under the Amended and Restated Option
Plan, either as a fixed number or a fixed percentage of the Company’s issued and outstanding common shares; and

 

		(e)	any amendment to the amendment provisions described above.

 

Finally, the TSX Provisions contain a net
settlement alternative which will provide that, in lieu of exercising an Option by delivery of an exercise notice along with payment
of the exercise price, with the prior written approval of the Company, which may be granted or withheld in the Company’s
sole discretion, any Option holder or the personal representative of such Option holder may elect to transfer and dispose of a
specified number of Options to the Company in exchange for a number of Common Shares having a fair market value equal to the intrinsic
value of such Options disposed of and transferred to the Company. Upon the net settlement of Options (the “Disposed Options”),
the Company shall deliver to the Option holder, that number of fully paid and non-assessable Common Shares (“X”) equal
to the number of Disposed Options (“Y”) multiplied by the quotient obtained by dividing the result of the Market Price
of one Common Share (“B”) less the exercise price per Common Share (“A”) by the Market Price of one Common
Share (“B”). Expressed as a formula, such number of Common Shares shall be computed as follows:

 

X = (Y) x (B - A)

                 (B)

 

Approval of Amendment and Restatement of Option Plan

 

If approved by shareholders, the Amended
and Restated Option Plan will become effective and replace the Option Plan in its entirety.

 

To be approved, the Option Plan Amendment
Resolution must be passed by a majority of the votes cast by the holders of Common Shares at the Meeting. Management unanimously
recommends a vote “for” in respect of the Option Plan Amendment Resolution.

 

    - 19 -

     

    

 

“BE IT RESOLVED AS AN ORDINARY RESOLUTION THAT:

 

1. The Company is hereby authorized to
adopt the Amended and Restated Option Plan in substantially the form appended hereto as Schedule A to be effective from the date
determined by the Board of Directors of the Company and shall thereafter continue and remain in effect until further ratification
is required pursuant to the rules of the TSXV, TSX (if applicable) or other applicable regulatory requirements.

 

2.The Option Plan shall continue and
remain in effect until the earlier of (i) the Amended and Restated Option Plan being declared effective by the Board of Directors
of the Company and (ii) such time as further ratification is required pursuant to the rules of the TSXV or other applicable regulatory
requirements.

 

3.Any one director or executive officer
of the Company is authorized and directed, on behalf of the Company, to take all necessary steps and proceedings and to execute,
deliver and file any and all declarations, agreements, documents and other instruments and do all such other acts and things that
may be necessary or desirable to give effect to this ordinary resolution.”

 

CORPORATE GOVERNANCE

 

General

 

Corporate governance refers to the policies
and structure of the board of directors of a corporation, whose members are elected by and are accountable to the shareholders
of the corporation. Corporate governance encourages establishing a reasonable degree of independence of the board of directors
from executive management and adoption of policies to ensure the board of directors recognizes the principles of good management.
The Board is committed to sound corporate governance practices, as such practices are both in the interests of shareholders and
help to contribute to effective and efficient decision-making.

 

The Board believes that good corporate
governance improves corporate performance and benefits all shareholders. The Canadian Securities Administrators (the “CSA”)
have adopted National Policy 58-201 Corporate Governance Guidelines, which provides non-prescriptive guidelines on corporate
governance practices for reporting issuers such as the Company. In addition, the CSA have implemented National Instrument
58-101 Disclosure of Corporate Governance Practices (“NI 58-101”), which prescribes certain disclosure
by the Company of its corporate governance practices. This section sets out the Company’s approach to corporate governance
and addresses the Company’s compliance with NI 58-101.

 

Board of Directors

 

The Board currently consists of six directors:
Robert W. Rieder (President and CEO), Richard M. Gilckman (Chairman of the Board), Marianne Sadar (Chief Scientific Officer), Raymond
Andersen (Chief Technical Officer), Gary Sollis and Franklin M. Berger.

 

The Company’s approach to corporate governance
is set forth below.

 

    - 20 -

     

    

 

Mandate of the Board

 

The Board assumes responsibility for the stewardship of the
Company and the creation of shareholder value. The Board is responsible for:

 

(a) ensuring that
management develops and implements a strategic plan that takes into account market realities and regulatory compliance;

 

(b) upholding a
comprehensive policy for communications with shareholders and the public at large;

 

(c) developing and
formalizing the responsibilities for each member of the Board, including the responsibilities of the CEO vis-à-vis
corporate objectives;

 

 (d) ensuring that the risk management of ESSA is prudently addressed; and

 

 (e) overseeing succession planning for management.

 

The frequency of meetings of the Board
and the nature of agenda items may change from year to year depending upon the activities of ESSA. However, the Board meets at
least quarterly and at each meeting there is a review of the business of ESSA.

 

The Board facilitates its exercise of independent
supervision over the Company’s management through frequent meetings of the Board being held to obtain an update on significant
corporate activities and plans, both with and without members of the Company’s management being in attendance. Further, the
independent directors of the Board hold, at a minimum, two meetings annually without the presence of non-independent directors.

 

The Board is composed of six directors,
three of whom qualify as independent directors. For this purpose, a director is independent if he or she has no direct or indirect
“material relationship” with ESSA. A “material relationship” is a relationship which could, in the view
of the Board, be reasonably expected to interfere with the exercise of the director’s independent judgment. An individual
who has been an employee or executive officer of the Company within the last three years is considered to have a material relationship
with the Company.

 

Of the directors, Richard Glickman, Gary
Sollis and Franklin M. Berger are considered independent. Three directors: (i) Bob Rieder, President and Chief Executive Officer
of the Company; (ii) Marianne Sadar, Chief Scientific Officer of the Company; and (iii) Raymond Andersen, Secretary and Chief Technical
Officer of the Company are considered not independent.

 

The size of the Company is such that all
the Company’s operations are conducted by a small management team which is also represented on the Board. The Board believes
that management is effectively supervised by the three independent directors, as the independent directors are actively and regularly
involved in reviewing the operations of the Company and have regular and full access to management not represented on the Board.

 

Composition of the Board is such that the
independent directors have significant experience in corporate affairs. As a result, these Board members are able to provide significant
and valuable independent supervision over management.

 

    - 21 -

     

    

 

Directorships

 

The following directors of the Company are also directors of
other reporting issuers as set out below:

 

		 		 	Name of Exchange Listed
	Name of Director	 	Name of Reporting Issuer	 	On
	Robert W. Rieder	 	Cardiome Pharma Corp.	 	TSX, NASDAQ
	Richard Glickman	 	Cardiome Pharma Corp.	 	TSX, NASDAQ
	 	 	Aurinia Pharmaceuticals Corp.	 	TSX
	Franklin M. Berger	 	Five Prime Therapeutics, Inc., Immune
    Design Corp.,	 	TSX, NASDAQ
	 	 	Bellus Health, Inc.	 	 

 

Orientation and Continuing Education

 

ESSA will provide new directors with copies
of relevant financial, technical and other information regarding its research and development programs.

 

Board members are also encouraged to communicate
with management and the Auditor, and to keep themselves current with industry trends and developments. Board members have full
access to the Company’s records. The Company will support Board members who wish to engage in ongoing director’s education
in particular areas to maintain the skill and knowledge necessary to effectively perform their duties.

 

Ethical Business Conduct

 

The Board will from time to time discuss
and emphasize the importance of matters relating to conflicts of interest, protection and proper use of corporate assets and opportunities,
confidentiality of corporate information, compliance with laws and the reporting of any illegal or unethical behavior. Although
ESSA has not adopted a written code of business conduct and ethics, in connection with the Company’s application to list
its Common Shares on the NASDAQ, ESSA plans to adopt a written code of business conduct and ethics.

 

Nomination of Directors

 

It is the view of the Board that all directors,
individually and collectively, should assume responsibility for nominating directors. The Board is responsible for identifying
and recommending potential nominees for directorship and senior management.

 

Assessments

 

The Board and each individual director
are regularly assessed on effectiveness and contribution. The assessment considers and takes into account:

 

		·

	in the case of the Board, its mandate; and

 

		

·

	in the case of an individual director, the competencies and skills each individual director is
expected to possess.

 

    - 22 -

     

    

 

Compensation

 

The CEO’s compensation is determined
by the Board (excluding the CEO), based on the recommendation of the Board’s Compensation Committee (the “Compensation
Committee”). The Compensation Committee, in making its recommendations regarding the CEO’s compensation, reviews
and considers the Company’s corporate goals and objectives as well as performance.

 

For further information, see heading “Statement
of Executive Compensation – Compensation Discussion and Analysis – Compensation Committee”.

 

Board Committees

 

The Board believes that its proper governance
and effectiveness in carrying out its duties is greatly enhanced by the use of committees. To assist in the discharge of its responsibilities,
the Board has designated two standing committees: the Audit Committee and the Compensation Committee.

 

The Audit Committee oversees the financial
reporting procedures to satisfy itself that there are adequate internal controls over accounting and financial reporting systems.
The Audit Committee sets out its duties and responsibilities in the Audit Committee Mandate of the Company. For further information
about the Audit Committee, see the heading “Audit Committee and Relationship with Auditor” above.

 

The Compensation Committee is composed
of Gary Sollis (Chair), Richard Glickman, and Franklin Berger. See heading “Director Biographies” above for
a description of the education and experience of each of the members of the Compensation Committee that is relevant to their performance
as a Compensation Committee member. All are familiar with designing and reviewing executive compensation packages through their
roles within those companies. For further information on the Compensation Committee, see the heading “Statement of Executive
Compensation – Compensation Discussion and Analysis – Compensation Committee”.

 

Other Board Committees

 

The Board has from time to time designated
and may in the future designate ad hoc committees to assist in the discharge of its responsibilities. During the most recently
completed financial year, the Company did not designate any ad hoc committees.

 

STATEMENT OF EXECUTIVE COMPENSATION

 

Prior to obtaining a receipt
on December 8, 2014 for the long form prospectus of the Company dated December 5, 2014 from the securities regulatory authority
in each of Alberta, British Columbia and Ontario, the Company was not a reporting issuer in any jurisdiction. As a result, certain
information required by Form 51-102F6 – Statement of Executive Compensation (“Form 51-102F6”) has
been omitted pursuant to Section 1.3(8) of Form 51-102F6.

 

Named Executive Officers

 

The following individuals are defined as
“named executive officers” or “NEOs” pursuant to Form 51-102F6 – Statement of Executive
Compensation:

 

		(a)	the CEO of ESSA or any person that acted in a similar capacity during the most recently completed
fiscal year;

 

    - 23 -

     

    

 

		(b)	the CFO of ESSA or any person that acted in a similar capacity during the most recently completed
fiscal year;

 

		(c)	each of the three most highly compensated executive officers of ESSA, including its subsidiary
ESSA Pharmaceuticals Corp., other than the CEO and the CFO, who were serving as executive officers at the end of the most recently
completed fiscal year and whose total compensation was individually more than $150,000 per year; and

 

		(d)	any additional individuals for whom disclosure would have been provided under (c) except that the
individual was not serving as an executive officer of ESSA at the end of the most recently completed financial year.

 

Each of Robert W. Rieder, President and
CEO, and David Wood, CFO, is an NEO of the Company for purposes of this disclosure.

 

Compensation Discussion and Analysis

 

Compensation Committee

 

As of September 30, 2014, ESSA did not
have a compensation committee of the Board. All compensation matters were dealt with by the entire Board, including compensation
of the Board itself. At a meeting held on December 19, 2014, the Board formed a Compensation Committee. The Compensation Committee
is comprised of Gary Sollis (Chair), Richard Glickman and Franklin Berger. The Compensation Committee is responsible for reviewing
the compensation plans and severance arrangements for management, to ensure they are commensurate with comparable companies. For
a detailed description of the relevant experience of each member of the Compensation Committee, please see the section “Election
of Directors – Director Biographies” above. The Compensation Committee: 

 

		·

	reviews and makes recommendations to the Board about the objectives, performance and compensation
of the CEO;

 

		·

	reviews the recommendations of the CEO regarding:

 

		·

	compensation of the senior executive officers of the Company that report to the CEO;

 

		

·

	the compensation policy of the Company (the “Executive Compensation Program”),
including internal structure, annual review and relationship to market levels and changes to ensure the relationship between senior
management performance and compensation is appropriate; and

 

		·

	significant changes in Company’s benefit plan and human resources policies with emphasis
on overall strategy and programs relating to the recruitment, development and retention of personnel;

 

		·

	recommends the issuance of stock options to employees, consultants, and directors which the Board
then decides whether to approve; and

 

		·

	reviews overall compensation programs.

 

Factors that are taken into consideration when making compensation
decisions include:

 

	 	·	the financial resources available or expected to be available to the Company;

 

		·

	comparative compensations levels for companies of ESSA’s size
in the biopharmaceutical industry; 

 

    - 24 -

     

    

 

 

		·	the capabilities of individual contributors
to the Company’s success; 

 

		·	the reasonable compensation expectations
of the individual contributor; and 

 

		·	relative equity with other ESSA contributors.

 

Compensation Discussion and Analysis

 

ESSA’s compensation philosophy for NEOs
is focused on its belief that capable and qualified employees are critical to the Company’s success. Therefore, its compensation
plan is designed to attract the very best individuals in each expertise arena and to use salaries and long term incentive compensation
in the form of stock options or other suitable long-term incentives to attract and retain such employees. In making its determinations
regarding the various elements of executive stock option grants, ESSA will seek to meet the following objectives:

 

(a)to attract, retain and motivate
talented executives who create and sustain ESSA’s continued success within the context of compensation paid by other companies
of comparable size engaged in similar business in appropriate regions;

 

		(b)	to align the interests of the ESSA’s NEOs with the interests of shareholders of ESSA; and

 

		(c)	to incent extraordinary performance from the Company’s key employees.

 

Elements of Compensation

 

Base Salary – The base
salary review of any NEO takes into consideration the current competitive market conditions, experience, proven or expected
performance, and the particular skills of the NEO. Base salary is not evaluated against a formal “peer group”.
The base salaries for NEOs of ESSA as of the Company’s most recently completed financial year were:

 

	NEO	 	Base Salary
	Robert W. Rieder (CEO)	 	US$250,000/year
	David Wood (CFO)	 	C$240,000/year

 

Subsequent to September 30, 2014, the annual
base salary of Mr. Rieder was increased to US$340,000, and the annual base salary of Mr. Wood was increased to C$260,000.

 

Performance-Based Cash Bonuses
– Cash bonuses are not a normal part of ESSA’s executive compensation. However, the Company may elect to utilize
such incentives where the role-related context and competitive environment suggest that such a compensation modality is
appropriate. When and if utilized, the amount of cash bonus compensation will normally be paid on the basis of timely
achievement of specific pre-agreed milestones. Each milestone will be selected based upon consideration of its impact on
shareholder value creation and the ability of the Company to achieve the milestone during a specific interval. The amount of
bonus compensation will be determined based upon achievement of the milestone, its importance to the Company’s near and
long term goals at the time such bonus is being considered, the bonus compensation awarded to similarly situated executives
in similarly situated development stage life-sciences companies or any other factors the Company may consider appropriate at
the time such performance-based bonuses are decided upon. The quantity of bonus will normally be a percentage of base salary
not to exceed 100%. However, in exceptional circumstances, the quantity of bonus paid may be connected to the shareholder
value creation embodied in the pre-agreed milestones.

 

    - 25 -

     

    

 

The bonuses available to the NEOs as of September 30, 2014 were:

 

	NEO	 	Bonus Payable
	Robert W. Rieder (CEO)	 	Up to 50% of Base Salary
	David Wood (CFO)	 	None

 

Up to the date of this Circular, the Company
has generally relied on a flexible and informal approach to executive compensation. Accordingly, the bonus noted above of up to
50% of base salary available to Mr. Rieder was selected based on the Board’s collective agreement regarding an appropriate
bonus range and on discussions with Mr. Rieder about his expectations as CEO of the Company. Based on such discussions, the Board
also agreed on the specific achievements of the Company on which this bonus would be paid. The specific achievements on which the
2014 bonus was to be paid to Mr. Rieder were:

 

		·	successful awarding and approval by CPRIT
of US$12 million of CPRIT Grant funding to the Company; 

 

		·	hiring a Vice-President of Research and
Development; 

 

		·	hiring a Chief Medical Officer of the
Company; 

 

		·	the Company becoming a reporting issuer
in Canada; 

 

		·	the securities of the Company becoming
listed for trading on a stock exchange; and 

 

		·	completing 28-day GLP toxicology studies
with EPI-506 in two species. 

 

To date, the Company’s flexible and informal
approach to executive compensation has generally resulted in below-market compensation. However, given the recent progress of the
Company, including various successful financings, progress in building a management team for the Company that is appropriate for
the Company’s current operational scale, the Company’s listing of its Common Shares on the TSXV and application to
list the Common Shares on the NASDAQ, the Company expects to continue to formalize its executive compensation policies and practices
and to move total compensation levels closer to market.

 

In addition, ESSA agreed to pay Mr. Rieder
a cash bonus of US$50,000 upon the Company raising C$3,000,000 by completing a financing during his term of employment, and an
additional cash bonus of US$50,000 if the Company raises an additional C$7,000,000 through a financing during his term of employment.
Pursuant to the several financings completed in 2014 and 2015, the Company surpassed both its C$3,000,000 and C$7,000,000 financing
goals. Accordingly, the Company has paid a cash bonus of US$100,000 payable to Mr. Rieder. Further, in recognition of the Company’s
outstanding performance, on February 23, 2014, the Compensation Committee awarded an annual bonus of US$125,000 to Mr. Rieder for
the fiscal year ended September 30, 2014 and a one-time interim bonus of C$25,000 to Mr. Wood.

 

Stock Options

 

Options are a
key compensation element for companies such as ESSA. Because many of the most capable employees in ESSA’s industry work for
pharmaceutical companies who can offer attractive cash and bonus compensation and a high level of employment security, Options
represent a compensation element that balances the loss of employment security that such employees must accept when moving to a
small development-stage company like ESSA. Options are also an important component of aligning the objectives of ESSA employees
with those of shareholders. ESSA has issued significant Options positions to senior employees and lesser amounts to lower-level
employees. The precise amount of Options to be offered was governed by the importance of the role within ESSA, by the competitive
environment within which ESSA operates, and by the regulatory limits on stock option grants that cover organizations such
as ESSA. This reflects ESSA’s commitment to attracting and retaining world-level expertise to the Company. The Options granted
to the Company’s NEOs as of the Company’s most recently completed financial year are as follows:

 

    - 26 -

     

    

 

 

	NEO	 	Options
	Robert W. Rieder (CEO)	 	Nil
	David Wood (CFO)’	 	75,000 Options ($0.80 exercise price per Common Share, expiring May 20, 2019) and 200,000 Options ($2.00 exercise price per Common Share, expiring July 30, 2019)

 

Since the Company’s most recent financial
year end, the Company granted the following Options to its NEOs:

 

	NEO	 	Options
	Robert W. Rieder (CEO)	 	150,000 Options ($2.00 exercise price per Common Share, expiring December 31, 2019)
	David Wood (CFO)	 	Nil

 

Compensation Risks

 

In making its compensation-related decisions,
the Board carefully considers the risks implicitly or explicitly connected to such decisions. These risks include the risks associated
with employing executives who are not world-class in their capabilities and experience, the risk of losing capable but under-compensated
executives, and the financial risks connected to the Company’s operations, of which executive compensation is an important
part.

 

In adopting the compensation philosophy described above, the principal
risks identified by ESSA are:

 

		·	that the Company will be forced to raise
additional funding (causing dilution to shareholders) in order to attract and retain the calibre of executive employees that it
seeks; and 

 

		·	that the Company will have insufficient
funding to achieve its objectives. 

 

After careful consideration of these risks, the Board has adopted
the compensation policy described above.

 

NEO Compensation

 

As of September 30, 2014, ESSA had two NEOs: Bob Rieder, President
and CEO and David Wood, CFO.

 

Defined Benefits Plans

 

ESSA currently does not have a defined benefits pension plan.

 

Defined Contribution Plans

 

ESSA currently does not have a defined contribution plan.

 

Deferred Compensation Plans

 

    - 27 -

     

    

 

ESSA currently does not have a deferred compensation plan.

 

Termination and Change of Control Benefits

 

Except as described below, there are no contracts,
agreements, plans or arrangements that provide for payments to a NEO at, following, or in connection with any termination (whether
voluntary, involuntary or constructive), resignation, retirement, a change in control of the Company or its subsidiary or a change
in a NEO’s responsibilities (excluding perquisites and other personal benefits if the aggregate of this compensation is less
than $50,000).

 

In 2014, the Company entered into new employment
agreements with its NEOs, which provide for certain rights upon termination of employment or a change of control of ESSA. ESSA
believes that these provisions of the NEO employment agreements are reasonable in the context of similar-sized biopharmaceutical
companies. The Company expects to offer similar provisions to executive-level employees in the future.

 

Specific termination and change-of-control provisions of each NEO
include:

 

For Robert Rieder:

 

		·	A payment to the employee of one year of
base salary upon termination without cause, increasing to two years if the termination without cause occurs after a change of control
event or within 60 days prior to a change of control event where such event was under consideration at the time of termination.
Had Mr. Rieder’s employment been terminated without cause on September 30, 2014, he would have received US$250,000. Had Mr.
Rieder’s employment been terminated without cause after a change of control event or within 60 days prior to a change of
control event where such event was under consideration at the time of termination, he would have received US$500,000. 

 

		·	Immediate vesting of all Options upon
occurrence of a change of control event. Mr. Rieder held no Options on September 30, 2014. 

 

For David Wood:

 

		·	A payment to the employee of up to one
year of base salary for termination without cause, whether or not the termination was caused by a change of control event. Had
Mr. Wood been terminated without cause on September 30, 2014, whether or not the termination was caused by a change of control
event, he would have received up to C$240,000. 

 

		·	Immediate vesting of all Options upon
occurrence of a change of control event. As of September 30, 2014, Mr. Wood held 275,000 Options. 

 

Director Compensation

 

Prior to September 30, 2014, ESSA did not pay
any cash compensation to its independent directors. However, ESSA adopted a compensation plan for independent members of the Board
which became effective on January 1, 2015. Pursuant to this compensation plan, both cash payments and Options will be offered to
independent directors. Each independent director will receive a retainer of $12,000 per annum. In addition, the Chair of the Board
will receive a premium of $12,000 per annum. Independent directors will also be paid a cash fee of $1,000 per in-person meeting,
and $500 per teleconference meeting, and receive an Option grant of 75,000 Options, with 25,000 Options vesting upon appointment
to the Board, 25,000 vesting on the first anniversary of the grant and the remainder vesting on the second anniversary of the grant.
Directors who are officers, employees or consultants of the Company will receive no compensation under the terms of this compensation
plan.

 

    - 28 -

     

    

 

Incentive Plan Awards Outstanding

 

As at September 30, 2014, non-NEO directors
held 1,035,000 Options in the Company. During the fiscal year ended September 30, 2014, 185,000 Options were granted to non-NEO
directors, resulting in $41,721 vested or earned in the year ended September 30, 2014.

 

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION
PLANS

 

The shareholders of the Company approved the
Option Plan at the annual general meeting of shareholders held on September 4, 2014.

 

Equity Compensation Plan Information

 

	 	 	 	 	 	 	 	 	Number of securities	 
	 	 	 	 	 	 	 	 	remaining available for	 
	 	 	 	 	 	 	 	 	future issuance under	 
	 	 	Number of Securities to be	 	 	Weighted-average	 	 	equity compensation plans	 
	 	 	issued upon exercise of	 	 	exercise price of	 	 	(excluding securities	 
	 	 	outstanding options	 	 	outstanding options	 	 	reflected in column (a))	 
	Plan Category	 	(as at September 30, 2014)	 	 	(as at September 30, 2014)	 	 	(as at September 30, 2014)	 
	 	 	 	 	 	 	 	 	 	 
	Equity compensation plans approved by securityholders(1)	 	 	3,069,719	(2)	 	$	0.91	 	 	 	1,930,281	(3)
	Equity compensation plans not approved by securityholders	 	 	N/A	 	 	 	N/A	 	 	 	N/A	 
	Total	 	 	3,069,719	(2)	 	$	0.91	 	 	 	1,930,281	(3)

 

Notes: 

 

		(1)	The current fixed share Option Plan provides that the maximum number of Common Shares to be acquired
pursuant to Options granted under the Option Plan is 5,000,000 Common Shares. The Option Plan enables the directors, executive
officers, employees and consultants of the Company and its affiliates to participate in the growth and development of the Company
by providing such persons with the opportunity, through options to purchase Common Shares, to acquire an increased proprietary
interest in the Company that is aligned with the interests of the shareholders.

 

		(2)	This number represents 16.9% of the 18,144,322 issued and outstanding Common Shares as of the Record
Date.

 

		(3)	This number is derived from subtracting the total number of Options outstanding as at September
30, 2014 from the maximum number of Common Shares to be acquired pursuant to Options granted under the Option Plan.

 

Prior to September 4, 2014, ESSA did not have
in place a formal stock option plan. Options were previously issued by the Board on a case-by-case basis, reflecting the priorities
in place at each such time point. On September 4, 2014, ESSA adopted the Option Plan. The Option Plan is administered by the Board,
or by the Compensation Committee, in accordance with such terms and conditions as the Board may prescribe.

 

ESSA’s administration of the Option Plan
is consistent with the policies and rules of the TSXV and will comply with such other stock exchanges on which the Common Shares
may be listed in the future. Amendments to the terms of previously granted Options are subject to regulatory approval, if required.
If required by the TSXV, disinterested shareholder approval shall be obtained for any reduction in the option price of a previously
granted Option if the optionee is an insider of ESSA at the time of the proposed reduction in the option price.

 

    - 29 -

     

    

 

Subject to the approval of the TSXV, the Board
may terminate, suspend or amend the terms of the Option Plan, provided, that the Board may not do any of the following without
obtaining, within 12 months either before or after the Board’s adoption of a resolution authorizing such action, approval
by the affirmative votes of the holders of a majority of the voting securities of ESSA present, or represented, and entitled to
vote at a meeting duly held in accordance with the applicable corporate laws, and, where required, by way of disinterested shareholder
approval, or by the written consent of the holders of a majority of the securities of ESSA entitled to vote:

 

		(a)	reduce the exercise price of Options granted to insiders of ESSA (for the purposes of this section,
the term “insiders” has the meaning given thereto in Policy 1.1 – Interpretation of the TSXV Corporate
Finance Manual, namely: (a) a director or senior officer of the Company; (b) a director or senior officer of a company that is
an Insider or subsidiary of the Company; (c) a person that beneficially owns or controls, directly or indirectly, voting shares
carrying more than 10% of the voting rights attached to all outstanding voting shares of the Company, or (d) the Company itself
if it holds any of its own securities), if the holder of such Options is an insider of the Company at the time of such proposed
amendment;

 

		(b)	grant to insiders of ESSA, within a 12 month period, number of options exceeding 10% of the Company’s
issued Common Shares;

 

		(c)	issue to any one holder of Options, within a 12 month period, number of Common Shares exceeding
5% of the Company’s Common Shares;

 

		(d)	reserve for issuance Common Shares under the Option Plan where such reservation could result in
the number of Common Shares granted to insiders of ESSA exceeding 10% of the Company’s issued Common Shares;

 

		(e)	materially modify the requirements as to eligibility for participation in the Option Plan; or

 

		(f)	materially increase the benefits accruing to participants under the Option Plan,

 

however, the Board may amend the terms of the
Option Plan to comply with the requirements of any applicable regulatory authority, or as a result in the changes in the policies
of the TSXV relating to incentive stock options, without obtaining the approval of shareholders.

 

At the Meeting, Shareholders will be asked
to pass an ordinary resolution to approve the Amended and Restated Option Plan as described above. See the heading “Amendment
and Restatement of Stock Option Plan” above.

 

    - 30 -

     

    

 

INDEBTEDNESS OF DIRECTORS AND EXECUTIVE OFFICERS

 

Aggregate Indebtedness

 

As of this date of this Circular, there is
no indebtedness owing to the Company or the Company’s subsidiary from any of our current, or former, officers, directors,
or employees, including in respect of indebtedness to others where the indebtedness is the subject of a guarantee, support agreement,
letter of credit or other similar arrangement provided by the Company or the company’s subsidiary.

 

Indebtedness of Directors and Executive Officers under Securities
Purchase and Other Programs

 

No person who is, or at any time during the
most recently completed financial year was, a director or executive officer of the Company, and no associate of any such director
or officer is, or at any time since the beginning of the most recently completed financial year of the Company has been, indebted
to the Company or the company’s subsidiary, and no such persons owe a debt to another entity, which is the subject of a guarantee,
support agreement, letter of credit or other similar arrangement provided by the Company or the company’s subsidiary.

 

INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS

 

This Management Information Circular briefly
describes (and, where practicable, states the approximate amount) of any material interest, direct or indirect, of any informed
person of the Company, any proposed director of the Company, or any associate or affiliate of any informed person or proposed director,
in any transaction since the commencement of the Company’s most recently completed financial year or in any proposed transaction
which has materially affected or would materially affect the Company or any of its subsidiaries.

 

MANAGEMENT CONTRACTS

 

Except as set out herein, there are no management
functions of the Company which are to any substantial degree performed by a person or company other than the directors or executive
officers of the Company.

 

DIRECTORS’ AND OFFICERS’ LIABILITY INSURANCE

 

We carry directors’ and officers’
liability insurance for our directors and officers. Currently, this insurance covers the liabilities of our directors and officers
up to a maximum claim of $10,000,000 for each loss at an annual premium of $68,000. We believe this level of coverage is appropriate
for a biopharmaceutical company at our stage of development. In addition, the Company has entered into indemnification agreements
with each of its directors and officers. The indemnification agreements generally require that the Company indemnify and hold the
indemnitees harmless to the greatest extent permitted by law for liabilities arising out of the indemnitees’ service to the
Company as directors and officers, if the indemnitees acted honestly and in good faith with a view to the best interests of the
Company and, with respect to criminal and administrative actions or other non-civil proceedings that are enforced by monetary penalty,
if the indemnitee had reasonable grounds to believe that his or her conduct was lawful. The indemnification agreements also provide
for the advancing of defence expenses to the indemnitees by the Company.

 

    - 31 -

     

    

 

ADDITIONAL INFORMATION

 

Additional information relating to the Company
is available on SEDAR at www.sedar.com. Financial information is provided in the Company’s comparative financial statements
and management discussion and analysis for its most recently completed financial year ended September 30, 2014. The Company will
provide to any person or company, upon request, one copy of the comparative financial statements of the Company filed with the
applicable securities regulatory authorities for the Company’s two most recently completed financial years in respect to
which such financial statements have been issued, together with the report of the auditor, related management’s discussion
and analysis and any interim financial statements of the Company filed with the applicable securities regulatory authorities subsequent
to the filing of the annual financial statements.

 

Copies of the above documents will be provided
free of charge to security holders of the Company. The Company may require payment of a reasonable charge from any person or company
who is not a security holder of the Company, who requests a copy of any such document. The foregoing documents are also available
on SEDAR at www.sedar.com.

 

OTHER MATTERS

 

The Board is not aware of any other matters
which it anticipates will come before the Meeting as of the date of mailing of this Management Information Circular.

 

    - 32 -

     

    

 

DIRECTORS’ APPROVAL

 

The contents of this Management Information Circular and its distribution
to shareholders have been approved by the Board of the Company.

 

DATED at Vancouver, British Columbia, April 21, 2015.

 

	BY ORDER OF THE BOARD
	 
	(signed) “Robert W. Rieder”	 
	 
	Robert W. Rieder
	President, Chief Executive Officer and Director

 

 

     

     

    

 

Schedule A

 

Amended and Restated Option Plan

 

(See attached)

 

     

     

    

 

ESSA PHARMA INC.

 

[·],
2015

 

STOCK OPTION PLAN

 

Approved by the Board on April 16, 2015

 

     

     

    

 

 

TABLE OF CONTENTS

 

	ARTICLE 1 DEFINITIONS AND INTERPRETATION	1
	 	 	 
	1.1	Definitions	1
	1.2	Choice of Law	6
	1.3	Headings	6
	 	 	 
	ARTICLE 2 PURPOSE AND PARTICIPATION	6
	 	 	 
	2.1	Purpose	6
	2.2	Eligibility	6
	2.3	Notification of Award	7
	2.4	Copy of Plan	7
	2.5	Limitation	7
	 	 	 
	ARTICLE 3 TERMS AND CONDITIONS OF OPTIONS	7
	 	 	 
	3.1	Board to Issue Common Shares	7
	3.2	Number of Common Shares	7
	3.3	Option Details	8
	3.4	Term of Option	8
	3.5	Termination of Options	8
	3.6	Exercise Price	9
	3.7	Additional Terms	9
	3.8	Going Public Agreements	10
	3.9	Assignment of Options	10
	3.10	Adjustment of Options	11
	3.11	Option Grant and Vesting Terms	12
	3.12	U.S. Participants	12
	 	 	 
	ARTICLE 4 EXERCISE OF OPTION	13
	 	 	 
	4.1	Exercise of Option	13
	4.2	Issue of Share Certificates	14
	4.3	Condition of Issue	14
	4.4	Tax Withholding and Procedures	14
	 	 	 
	ARTICLE 5 TSX PROVISIONS	15
	 	 	 
	5.1	Application	15
	5.2	Definitions	15
	5.3	Eligibility	16
	5.4	Limitations on Issue	16
	5.5	Number of Common Shares	16
	5.6	Amendment to Plan or Options by the Board	17
	5.7	Amendments Requiring Disinterested Shareholder Approval	18
	5.8	Net Settlement	18
	5.9	Plan Subject to TSX Policies	19

 

    	 	- i -	 

     

    

 

	ARTICLE 6 ADMINISTRATION	19
	 	 	 
	6.1	Administration	19
	6.2	Interpretation	19
	 	 	 
	ARTICLE 7 AMENDMENT, TERMINATION AND NOTICE	19
	 	 	 
	7.1	Termination and Amendment of Plan	19
	7.2	Approvals	20
	7.3	Termination	20
	7.4	Agreement	20
	7.5	Notice	20
	 	 	 
	SCHEDULE A	A-1
	 	 
	SCHEDULE B	B-1
	 	 
	SCHEDULE C	C-1

 

    	 	- ii -	 

     

    

 

STOCK OPTION PLAN

 

ARTICLE 1

DEFINITIONS AND INTERPRETATION

 

		1.1	Definitions

 

Subject to Article 5, as used herein, unless there is something
in the subject matter or context inconsistent therewith, the following terms will have the meanings set forth below:

 

		(a)	“Administrator” means, initially, the Chief Financial Officer of the Company
and thereafter will mean such director or other senior officer or employee of the Company as may be designated as Administrator
by the Board from time to time.

 

		(b)	“Affiliate” has the meaning given to such term in the policy manual of the TSX-V.

 

		(c)	“Award Date” means the date on which the Board awards a particular Option or
such other effective award date determined by the Board.

 

		(d)	“Blackout Period” has the meaning given to that term in the policy manual of
the TSX-V.

 

		(e)	“Board” means the board of directors of the Company, or any committee thereof
to which the board of directors of the Company has delegated the power to administer and grant Options under the Plan.

 

		(f)	“Cause” means:

 

		(i)	Cause as such term is defined in the written employment agreement between the Company and the Optionee;
or

 

		(ii)	in the event there is no written employment agreement between the Company and the Optionee or Cause
is not defined therein, the usual meaning of just cause under the common law or the laws of the jurisdiction in which the Optionee
is employed.

 

		(g)	“Change of Control” means the occurrence of any of the following events:

 

		(i)	the direct or indirect acquisition or conversion of more than 50% of the issued and outstanding
shares of the Company by a Person or group of Persons acting in concert, other than through an employee share purchase plan or
employee share ownership plan and other than by Persons who are or who are controlled by, the existing shareholders of the Company;

 

		(ii)	a merger, amalgamation or arrangement of the Company or of the voting shares of the Company where
the voting shares of the resulting merged, amalgamated or arranged company, as applicable, are owned or controlled by shareholders
of whom more than 50% are not the same as the shareholders of the Company immediately prior to the merger, amalgamation or arrangement;
or

 

     

     

    

 

		(iii)	a sale by the Company of greater than 50% of the fair market value of the assets of the Company,
through one or a series of transactions, to an entity that is not controlled by either the shareholders of the Company or by the
Company.

 

		(h)	“Code” has the meaning given to that term under Section 3.12.

 

		(i)	“Common Share” or “Common Shares” means, as the case may
be, one or more common shares in the capital of the Company.

 

		(j)	“Company” means ESSA Pharma Inc., a company incorporated under the laws of the
Province of British Columbia.

 

		(k)	“Consultant” means an individual or Consultant Company, other than an Employee,
a Director or an Officer of the Company, that:

 

		(i)	is engaged to provide on a bona fide basis, consulting, technical, management or other services
to the Company or an Affiliate, other than services provided in relation to a distribution;

 

		(ii)	provides the services under a written contract between the Company or an Affiliate of the Company
and the individual or the Consultant Company;

 

		(iii)	in the reasonable opinion of the Company, spends or will spend a significant amount of time and
attention to the affairs and business of the Company or an Affiliate; and

 

		(iv)	has a relationship with the Company or an Affiliate that enables the individual to be knowledgeable
about the business and affairs of the Company.

 

		(l)	“Consultant Company” means for an individual Consultant, a company or partnership
of which the individual is an employee, shareholder or partner.

 

		(m)	“Director” means any individual holding the office of director of the Company.

 

		(n)	“Disability” means a medically determinable physical or mental impairment expected
to result in death or to last for a continuous period of not less than 12 months which causes an individual to be unable to engage
in any substantial gainful activity.

 

		(o)	“Disposed Options” has the meaning given to that term under Section 5.8.

 

		(p)	“Employee” means

 

		(i)	an individual who is considered an employee of the Company or its subsidiary under the Income
Tax Act (Canada);

 

		(ii)	an individual who works full-time for the Company or its subsidiary providing services normally
provided by an employee and who is subject to the same control and direction by the Company over the details and methods of work
as an employee of the Company, but for whom income tax deductions are not made at source;

 

    - 2 -

     

    

 

		(iii)	an individual who works for the Company or its subsidiary on a continuing and regular basis for
a minimum amount of time per week providing services normally provided by an employee and who is subject to the same control and
direction by the Company over the details and methods of work as an employee of the Company, but for whom income tax deductions
are not made at source; or

 

		(iv)	a Management Company Employee.

 

		(q)	“Equity Securities” means:

 

		(i)	shares or any other security of the Company that carries the residual right to participate in the
earnings of the Company and, on liquidation, dissolution or winding-up, in the assets of the Company, whether or not the security
carries voting rights;

 

		(ii)	any warrants, options or rights entitling the holders thereof to purchase or acquire any such securities;
or

 

		(iii)	any securities issued by the Company which are convertible or exchangeable into such securities.

 

		(r)	“Exchange” means a stock exchange, inter-dealer quotation network or other organized
trading facilities on which the Common Shares are listed.

 

		(s)	“Exercise Notice” means the notice respecting the exercise of an Option, in
the form set out as Schedule B hereto, duly executed by the Optionee.

 

		(t)	“Exercise Period” means the period during which a particular Option may be exercised
and is the period from and including the Award Date through to and including the Expiry Date.

 

		(u)	“Exercise Price” means the price at which an Option may be exercised as determined
in accordance with Section 3.6.

 

		(v)	“Expiry Date” means the expiry date of an Option as specified in the Option
Certificate.

 

		(w)	“Going Public Transaction” means: (i) the offering and sale to the public of
securities of the Company, or direct listing application of the Company, in connection with which the securities of the Company
are listed or quoted on an organized trading facility; (ii) a reverse takeover by the Company of any corporation listed on, or
that obtains a listing of its principal voting securities on, an organized trading facility; (iii) the sale of all or substantially
all of the issued and outstanding shares in the capital of the Company for securities that are listed or quoted on an organized
trading facility; or (iv) the amalgamation, merger, arrangement, reverse takeover or any other corporate transaction involving
the Company with or into another entity pursuant to which securities of the resulting issuer from such transaction are listed or
quoted on an organized trading facility.

 

		(x)	“Guardian” means the guardian, if any, appointed for an Optionee.

 

		(y)	“Insider” has the meaning given to such term in the policy manual of the TSX-V.

 

    - 3 -

     

    

 

		(z)	“Investor Relations Activities” means any activities or oral or written communications,
by or on behalf of the Company or shareholder of the Company, that promote or reasonably could be expected to promote the purchase
or sale of securities of the Company, but does not include:

 

		(i)	the dissemination of information provided, or records prepared, in the ordinary course of business
of the Company:

 

		A.	to promote the sale of products or services of the Company; or

 

		B.	to raise public awareness of the Company;

 

that cannot reasonably be considered to promote the
purchase or sale of securities of the Company;

 

		(ii)	activities or communications necessary to comply with the requirements of:

 

		A.	applicable securities laws; and

 

		B.	Exchange requirements or the by-laws, rules or other regulatory instruments of any other self-regulatory
body or Exchange having jurisdiction over the Company;

 

		(iii)	communications by a publisher of, or writer for, a newspaper, magazine or business or financial
publication, that is of general and regular paid circulation, distributed only to subscribers to it for value or to purchasers
of it, if:

 

		A.	the communication is only through the newspaper, magazine or publication; and

 

		B.	the publisher or writer receives no commission or other consideration other than for acting in
the capacity of publisher or writer; or

 

		(iv)	activities or communications that may be otherwise specified by an Exchange.

 

		(aa)	“ISO” has the meaning given to that term under Section 3.12.

 

		(bb)	“Management Company Employee” means an individual employed by a Person providing
management services to the Company, which are required for the ongoing successful operation of the business enterprise of the Company,
but excluding a Person engaged in Investor Relations Activities.

 

		(cc)	“Market Price” means an amount which is not less than the closing market price
for the Company’s Common Shares on the trading day prior to the date of grant of the Options.

 

		(dd)	“Net Settlement” has the meaning given to that term under Section 5.8.

 

		(ee)	“Offer” has the meaning given to such term in Section 3.10(f).

 

    - 4 -

     

    

 

		(ff)	“Officer” means any individual who is serving as a duly appointed officer of
the Company.

 

		(gg)	“Option” means an option to acquire Common Shares, awarded to a Director, Officer,
Employee or Consultant, including all options granted under the Plan or any prior version of the Plan or pursuant to individual
option agreements.

 

		(hh)	“Option Certificate” means the certificate, in the form set out as Schedule
A hereto, evidencing an Option.

 

		(ii)	“Optionee” means a Person to whom an Option has been granted hereunder.

 

		(jj)	“Person” means any individual, partnership, joint venture, syndicate, sole proprietorship,
company or corporation with or without share capital, trust, trustee, executor, administrator, or other legal personal representatives,
regulatory body or agency, government or governmental agency, authority or entity howsoever designated or constituted.

 

		(kk)	“Personal Representative” means:

 

		(i)	in the case of a deceased Optionee, the executor or administrator of the deceased duly appointed
by law or by a court or public authority having jurisdiction to do so; and

 

		(ii)	in the case of an Optionee who for any reason is unable to manage his or her affairs, the person
entitled by law to act on behalf of such Optionee.

 

		(ll)	“Plan” means this stock option plan.

 

		(mm)	“Qualified Successor” means a Person who is entitled to ownership of an Option
upon the death of an Optionee, pursuant to a will or the applicable laws of descent and distribution upon death.

 

		(nn)	“Regulatory Authorities” means all stock exchanges, inter-dealer quotation networks
and other organized trading facilities on which the Common Shares are listed and all securities commissions or similar securities
regulatory bodies having jurisdiction over the Company.

 

		(oo)	“Termination Date” means:

 

		(i)	in the case of the resignation of the Optionee’s employment or the termination of the Optionee’s
consulting or service contract by the Optionee, the date that the Optionee provides notice of such resignation or termination to
the Company; or

 

		(ii)	in the case of the termination of the Optionee’s employment or consulting or service contract
by the Company for any reason other than death or disability, the date that the Company delivers written notice of termination
of the Optionee’s employment or consulting or service contract to the Optionee; or

 

    - 5 -

     

    

 

		(iii)	in the case of the expiry of a fixed-term employment or consulting or service contract that is
not renewed or extended, the last day of the term.

 

		(pp)	“Transfer” includes any sale, exchange, assignment, gift, bequest, disposition,
mortgage, charge, pledge, encumbrance, grant of a security interest or other arrangement by which possession, legal title or beneficial
ownership passes from one Person to another, or to the same Person in a different capacity, whether or not voluntarily and whether
or not for value, and any agreement to effect any of the foregoing, including any sale or exchange pursuant to a plan of arrangement,
merger, consolidation, acquisition or similar transaction; and the words “Transferred”, “Transferring”
and similar words have corresponding meanings.

 

		(qq)	“TSX-V” means the TSX Venture Exchange.

 

		(rr)	“U.S. Participant” has the meaning given to that term under Section 3.12.

 

		1.2	Choice of Law 

 

The Plan is established under, and the
provisions of the Plan will be subject to and interpreted and construed in accordance with, the laws of the Province of British
Columbia.

 

		1.3	Headings

 

The headings used herein are for convenience only and are not
to affect the interpretation of the Plan.

 

ARTICLE 2

PURPOSE AND PARTICIPATION

 

		2.1	Purpose

 

The purpose of the Plan is to provide the
Company with a share-related mechanism to attract, retain and motivate qualified Directors, Officers, Employees and Consultants,
to reward such of those Directors, Officers, Employees and Consultants as may be awarded Options under the Plan by the Board from
time to time for their contributions toward creating shareholder value through achievement of the short and long term goals of
the Company.

 

		2.2	Eligibility

 

The Board will, from time to time and in
its sole discretion, determine those Directors, Officers, Employees and Consultants, if any, to whom Options are to be awarded.
Subject to Article 5:

 

		(a)	Options may be granted to any Employee, Officer, Director or Consultant of the Company or any Affiliate.

 

		(b)	Notwithstanding Section 4.1 hereof, grants of Options to Insiders shall be subject to the policies
of the TSX-V so long as the Common Shares are listed on the TSX-V.

 

		(c)	No Option shall be granted to any Optionee unless the Board has determined that the grant of such
Option and the exercise thereof by the Optionee will not violate the securities laws of the jurisdiction in which the Optionee
resides.

 

    - 6 -

     

    

 

		(d)	The following restrictions on Option grants under the Plan apply:

 

		(i)	a Person can receive grants of no more than 5% of the issued and outstanding share capital of the
Company in any 12 month period, with the exception of a Consultant who may not receive grants of more than 2% of the issued and
outstanding share capital of the Company in any 12 month period; and

 

		(ii)	no more than an aggregate of 2% of the number of issued and outstanding Common Shares in the capital
of the Company may be reserved for issue upon exercise of option grants made to Persons employed to conduct Investor Relations
Activities at any one time.

 

		2.3	Notification of Award 

 

Following the approval by the Board of
the awarding of an Option, the Administrator will notify the Optionee in writing of the award and will enclose with such notice
the Option Certificate representing the Option so awarded.

 

		2.4	Copy of Plan

 

Each Optionee, concurrently with the notice
of the award of the Option, will be provided with a copy of the Plan. A copy of any amendment to the Plan will be promptly provided
by the Administrator to each Optionee.

 

		2.5	Limitation

 

The Plan does not give any Optionee that
is a Director or Officer the right to serve or continue to serve as a Director or Officer of the Company nor does it give any Optionee
that is an Employee the right to be or to continue to be employed with the Company, nor does it give any Optionee that is a Consultant
the right to have a consulting relationship with the Company or provide services to the Company.

 

ARTICLE 3

TERMS AND CONDITIONS OF OPTIONS

 

		3.1	Board to Issue Common Shares

 

The Common Shares to be issued to Optionees
upon the exercise of Options will be authorized and unissued Common Shares the issuance of which will have been authorized by the
Board.

 

		3.2	Number of Common Shares

 

Subject to Article 5 and subject to adjustment
as provided for in Section 3.10 hereof, the maximum number of Common Shares that will be available for Directors, Officers, Employees
and Consultants to acquire pursuant to Options will be 3,614,014 Common Shares, of which no more than 3,000,000 will be available
for Employees to acquire pursuant to ISOs. If any Option expires or otherwise terminates for any reason without having been exercised
in full, the number of Common Shares in respect of which the Option was not exercised will again be available for the purposes
of the Plan.

 

    - 7 -

     

    

 

		3.3	Option Details

 

With respect to each Option to be granted to an Optionee, the
Board shall specify the following terms in the Option between the Company and the Optionee:

 

		(a)	the Award Date;

 

		(b)	subject to Section 3.9, the term of the Option, provided that the Exercise Period shall in no event
be greater than ten (10) years following the Award Date, conditional upon the Exercise Period terminating during a Blackout Period,
in which case the Exercise Period would be extended by the number of days between the termination of the Exercise Period and the
expiration of the Blackout Period, such extension period not to exceed ten (10) business days;

 

		(c)	the Exercise Price, provided that the Exercise Price shall not be less than the Market Price;

 

		(d)	any vesting schedule contained in the Option Certificate upon which the exercise of the Option
is contingent; provided that, subject to compliance with the rules and policies of all applicable Regulatory Authorities, the Board
shall have complete discretion with respect to the terms of any such vesting schedule, including, without limitation, discretion
to:

 

		(i)	permit partial vesting in stated percentage amounts based on the term of such Option; and

 

		(ii)	permit full vesting after a stated period of time has passed from the Award Date;

 

		(e)	if the Optionee in respect of an Option grant is an Employee, a representation by the Company that
the Optionee is a bona fide Employee; and

 

		(f)	such other terms and conditions as the Board deems advisable and are consistent with the purposes
of this Plan.

 

		3.4	Term of Option

 

An Optionee may exercise an Option in whole
or in part at any time or from time to time during the Exercise Period. Any Option or part thereof not exercised within the Exercise
Period will terminate and become null, void and of no effect as of 5:00 p.m. local time in Vancouver, British Columbia on the Expiry
Date, conditional upon the Expiry Date occurring during a Blackout Period, in which case the Expiry Date would be extended by the
number of days between the specified Expiry Date and the expiration of the Blackout Period, such extension period not to exceed
ten (10) business days.

 

		3.5	Termination of Options

 

To the extent not earlier exercised or
terminated in accordance with Section 3.9 hereof, an Option shall terminate at the earliest
of the following dates:

 

		(a)	the termination date specified for such Option in the Option Certificate,
conditional upon the termination date occurring during a Blackout Period, in which case the termination date would be extended
by the number of days between the specified termination date and the expiration of the Blackout Period, such extension period not
to exceed ten (10) business days;

 

    - 8 -

     

    

 

		(b)	where the Optionee's position as an Employee, Consultant, Director or Officer of the Company or
any Affiliate is terminated for just cause, the date of such termination for just cause;

 

		(c)	where the Optionee's position as an Employee, Consultant, Officer or Director of the Company or
any Affiliate terminates for a reason other than the Optionee's Disability, death, or termination for just cause, 90 days after
such date of termination, provided that if an Optionee’s position with the Company changes from one of the said categories
to another category, such change shall not constitute termination for the purpose of this subsection 3.5(c); and

 

		(d)	the date of any sale, Transfer, assignment or hypothecation, or any attempted sale, Transfer, assignment
or hypothecation, of such Option in violation of Section 3.9 hereof.

 

		3.6	Exercise Price 

 

Subject to Article 5, the price at which
an Optionee may purchase a Common Share upon the exercise of an Option will be as set forth in the Option Certificate issued in
respect of such Option and in any event will not be less than the Market Price.

 

		3.7	Additional Terms

 

Notwithstanding the foregoing sections
of this Article 3, and subject to all applicable securities laws and regulations and the rules and policies of all applicable Regulatory
Authorities, the Board may attach other terms and conditions to the grant of a particular Option, such terms and conditions to
be referred to in a schedule attached to the Option Certificate. These terms and conditions may include, but are not necessarily
limited to, the following:

 

		(a)	providing that an Option expires on a date other than as provided for herein, provided that in
no case will an Option be exercisable later than the tenth anniversary of the Award Date of the Option, conditional upon the Expiry
Date occurring during a Blackout Period, in which case the Expiry Date would be extended by the number of days between the specified
Expiry Date and the expiration of the Blackout Period, such extension period not to exceed ten (10) business days;

 

		(b)	providing that a portion or portions of an Option vest after certain periods of time or upon the
occurrence of certain events, or expire after certain periods of time or upon the occurrence of certain events other than as provided
for herein; and

 

		(c)	providing that an Option be exercisable immediately, in full, notwithstanding that it has vesting
provisions, upon the occurrence of certain events, such as a friendly or hostile takeover bid for the Company.

 

    - 9 -

     

    

 

		3.8	Going Public Agreements

 

If the Company proceeds to list its Common
Shares on a public stock exchange or commences a public offering, each Optionee will promptly enter into all such escrow, pooling
or other agreements as are required by the securities regulatory authorities, the exchange, the agents or the underwriters in connection
with such listing or public offering.

 

		3.9	Assignment of Options

 

Subject to this Section 3.9 and Article 5, Options are non-assignable
and non-transferable.

 

		(a)	Death of Optionee – If the employment of an Optionee as an Employee or Consultant
of the Company or any Affiliate, or the position of an Optionee as a Director or Officer of the Company or any Affiliate,
terminates as a result of his or her death, any Options held by such Optionee shall pass to the Qualified Successor of the Optionee,
and shall be exercisable by the Qualified Successor for a period of 1 year following such death, provided that in no case shall
the Exercise Period of the Option extend beyond ten years from the Award Date.

 

		(b)	Disability of Optionee - If the employment of an Optionee as an Employee or
                                                               Consultant of the Company or any Affiliate, or the position of an Optionee as a Director or Officer of the Company or any
                                                               Affiliate, is terminated by the Company or any Affiliate by reason of such Optionee's Disability, any Option held by such
                                                               Optionee that could have been exercised immediately prior to such termination of service shall be exercisable by such
                                                               Optionee, or by his Guardian, for a period of 1 year following the termination of service of such Optionee.

 

		(c)	Disability and Death of Optionee - If an Optionee who has ceased to be employed by
the Company or any Affiliate by reason of such Optionee's Disability dies within 30 days after the termination of
such employment, any Option held by such Optionee that could have been exercised immediately prior to his or her death shall pass
to the Qualified Successor of such Optionee, and shall be exercisable by the Qualified Successor for a period of 1 year following
the death of such Optionee, provided that in no case shall the Exercise Period of the Option extend beyond five years from the
Award Date.

 

		(d)	Vesting - Options held by a Qualified Successor or exercisable by a Guardian
                                                               shall, during the period prior to their termination, continue to vest in accordance with any vesting schedule to which such
                                                               Options are subject.

 

		(e)	Deemed Non-Interruption of Employment - Employment shall be deemed to continue
                                                               intact during any military or sick leave or other bona fide leave of absence if the period of such leave does not
                                                               exceed 90 days or, if longer, for so long as the Optionee's right to reemployment with the Company or any Affiliate is
                                                               guaranteed either by statute or by contract. If the period of such leave exceeds 90 days and the Optionee's reemployment is
                                                               not so guaranteed, then his or her employment shall be deemed to have terminated on the ninety-first day of such leave.

 

    - 10 -

     

    

 

		(f)	Retirement - In the event of the termination of employment
of an Optionee who is an Employee at any time during the term of an Option by reason of the deemed retirement of
such Employee, as may be determined by the Board, in its sole discretion, then the rights to purchase Common Shares under
the Option which have accrued to the Optionee and remain unexercised at, or which accrue subsequent to, the date of his retirement
shall remain exercisable by the Optionee (or by the Optionee's legal personal representative or representatives if the Optionee
dies before the last date of exercise of the Option) for a period of 1 year following the retirement of such Optionee in accordance
with the terms of the Option.

 

		3.10	Adjustment of Options 

 

		(a)	Alteration in Capital Structure – If
there is any change in the Common Shares through or by means of a declaration of stock dividends of the Common Shares
or consolidations, subdivisions or reclassifications of the Common Shares, or otherwise, the number of Common Shares available
under the Plan, the Common Shares subject to any Option and the Exercise Price therefor shall be adjusted proportionately by the
Board and, if required, approved by the Regulatory Authorities having authority over the Company or the Plan, and such adjustment
shall be effective and binding for all purposes of the Plan. 

 

		(b)	Effect of Amalgamation, Merger or Arrangement –
If the Company amalgamates, merges or enters into a plan of arrangement with or into another corporation, any Common
Shares receivable on the exercise of an Option shall be converted into the securities, property or cash which the Optionee would
have received upon such amalgamation, merger or arrangement if the Optionee had exercised
his Option immediately prior to the record date applicable to such amalgamation, merger or arrangement, and the exercise price
shall be adjusted proportionately by the Board and such adjustment shall be binding for all purposes of the Plan.

 

		(c)	Acceleration on Change of Control – Upon a Change of Control, all Options
                                                               shall become immediately exercisable, notwithstanding any contingent vesting provisions to which such Options may have
                                                               otherwise been subject. Any proposed acceleration of vesting provisions are subject to the necessary approvals of the
                                                               applicable Regulatory Authorities.

 

		(d)	Acceleration of Date of Expiry or Vesting – The Board shall have the right
to accelerate the date of expiry of any portion of any Option or the vesting of any portion of any Option which remains
unvested, subject to the necessary approvals of the applicable Regulatory Authorities.

 

		(e)	Determinations to be made by Board – Adjustments and determinations under
                                                               this subsection (e) shall be made by the Board, whose decisions as to the adjustments or determination which shall be made,
                                                               and the extent thereof, shall be final, binding, and conclusive.

 

		(f)	Effect of a Take-over - If a bona fide offer (the
                                                               “Offer”) for Common Shares is made to an Optionee or to shareholders generally or to a class of
                                                               shareholders which includes the Optionee, which Offer constitutes a take-over bid within the meaning of Section 92 of the
                                                               British Columbia Securities Act, as amended from time to time, the Company shall, immediately upon receipt of notice
                                                               of the Offer, notify each Optionee of full particulars of the Offer, whereupon any Option held by an Optionee may be
                                                               exercised in whole or in part by the Optionee so as to permit the Optionee to tender the Common Shares received upon such
                                                               exercise (the “Optioned Shares”) to the Offer. If:

 

    - 11 -

     

    

 

 

		(i)	the Offer is not completed within the time specified therein; or

 

		(ii)	all of the Optioned Shares tendered by the Optionee pursuant to the Offer are not taken up and
paid for by the offeror pursuant thereto;

 

the Optioned Shares or, in the case
of clause (b) above, the Optioned Shares that are not taken up and paid for, may be returned by the Optionee to the Company and
reinstated as authorized but unissued Common Shares and with respect to such returned Optioned Shares, the Option shall be reinstated
as if it had not been exercised. If any Optioned Shares are returned to the Company under this Section, the Company shall refund
the Exercise Price to the Optionee for such Optioned Shares.

 

		(g)	No fractional Common Shares will be issued upon the exercise of an Option. Accordingly, if, as
a result of a consolidation, subdivision, conversion, exchange or reclassification of Common Shares, an Optionee would become entitled
to a fractional Common Share, such Optionee will have the right to purchase only the next lowest whole number of Common Shares
and no payment or other adjustment will be made with respect to the fractional interest so disregarded.

 

		3.11	Option Grant and Vesting Terms

 

Unless otherwise determined by the Board in
accordance with the terms and conditions of this Plan, Options will be granted by the Board. Subject to Article 5, the Board may
determine and impose terms upon which each Option shall become vested, provided that, if the Common Shares are listed on the TSX-V,
Options granted to Persons employed to conduct Investor Relations Activities, must vest in stages over 12 months with no more than
25% of the Options vesting in any three month period.

 

		3.12	U.S. Participants

 

Any Option granted under the Plan to an Optionee
who is a citizen or resident of the United States (including its territories, possessions and all areas subject to the jurisdiction)
(a “U.S. Participant”) may, at the sole discretion of the Company, be an incentive stock option (an “ISO”)
within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended, of the United States (the “Code”),
but only if so designated by the Company in the Option Certificate evidencing such Option. No provision of this Plan, as it may
be applied to a U.S. Participant with respect to Options which are designated as ISOs, shall be construed so as to be inconsistent
with any provision of Section 422 of the Code or the Treasury Regulations thereunder. Grants of Options to U.S. Participants which
are not designated as or otherwise do not qualify as ISOs will be treated as nonstatutory stock options for U.S. federal tax purposes.
Notwithstanding anything in this Plan contained to the contrary, the following provisions shall apply to ISOs granted to each U.S.
Participant:

 

		(a)	ISOs shall only be granted to individual U.S. Participants who are, at the time of grant, employees
of the Company within the meaning of the Code;

 

    - 12 -

     

    

 

		(b)	the aggregate fair market value (determined as of the time an ISO is granted) of the Common Shares
subject to ISOs exercisable for the first time by a U.S. Participant during any calendar year under this Plan and all other stock
option plans, within the meaning of Section 422 of the Code, of the Company shall not exceed One Hundred Thousand Dollars in U.S.
funds (U.S.$100,000);

 

		(c)	the Exercise Price for Common Shares under each ISO granted to a U.S. Participant pursuant to this
Plan shall be not less than fair market value of such Common Shares at the time the Option is granted, as determined in good faith
by the Board at such time (unless such ISO is granted pursuant to an assumption or substitution for another option in a manner
satisfying the provisions of Section 424(a) of the Code);

 

		(d)	if any U.S. Participant to whom an ISO is to be granted under the Plan at the time of the grant
of such ISO is the owner of shares possessing more than ten percent (10%) of the total combined voting power of all classes of
shares of the Company, then the following special provisions shall be applicable to the ISO granted to such individual:

 

		(i)	the Exercise Price (per share) subject to such ISO shall not be less than one hundred ten percent
(110%) of the fair market value of one Common Share at the time of grant; and

 

		(ii)	for the purposes of this Section 3.12 only, the Exercise Period shall not exceed five (5) years
from the date of grant;

 

		(e)	no ISO may be granted hereunder to a U.S. Participant following the expiration of ten (10) years
after the date on which this Plan is adopted by the Company or the date on which the Plan is approved by the shareholders of the
Company, whichever is earlier; and

 

		(f)	no ISO granted to a U.S. Participant under the Plan shall become exercisable unless and until the
Plan shall have been approved by the shareholders of the Company.

 

ARTICLE 4 

EXERCISE OF OPTION

 

		4.1	Exercise of Option

 

Except as provided pursuant to Sections 3.5,
3.9, and 3.10 hereof, no Option may be exercised unless the Optionee is, at the time of such exercise, a bona fide Employee,
Officer, Director or Consultant of the Company or any of its Affiliates or the Personal Representative of the Optionee, and shall
have been continuously such a bona fide Employee, Officer, Director or Consultant, as the case may be. An Optionee or the
Personal Representative of the Optionee may exercise the vested portion or portions of an Option in whole or in part at any time
or from time to time during the Exercise Period up to 5:00 p.m. local time in Vancouver, British Columbia on the Expiry Date by
delivering to the Administrator an Exercise Notice, the applicable Option Certificate and a certified cheque or bank draft payable
to “ESSA Pharma Inc.” in an amount equal to the aggregate Exercise Price of the Common Shares to be purchased
pursuant to the exercise of the Option.

 

    - 13 -

     

    

 

		4.2	Issue of Share Certificates

 

As soon as practicable following the receipt
of the Exercise Notice, the Administrator will, in his sole discretion, either cause to be delivered to the Optionee a certificate
for the Common Shares purchased by the Optionee or cause to be delivered to the Optionee a copy of such certificate and the original
of such certificate will be placed in the minute book of the Company. If the number of Common Shares in respect of which the Option
was exercised is less than the number of Common Shares subject to the Option Certificate surrendered, the Administrator will forward
a new Option Certificate to the Optionee concurrently with delivery of the share certificate for the balance of the Common Shares
available under the Option.

 

		4.3	Condition of Issue

 

The Options and the issue of Common Shares
by the Company pursuant to the exercise of Options are subject to the terms and conditions of the Plan and compliance with the
rules and policies of all applicable Regulatory Authorities with respect to the granting of such Options and the issuance and distribution
of such Common Shares, and to all applicable securities laws and regulations. The Optionee agrees to comply with all such laws,
regulations, rules and policies and agrees to furnish to the Company any information, reports or undertakings required to comply
with, and to fully cooperate with, the Company in complying with such laws, regulations, rules and policies.

 

		4.4	Tax Withholding and Procedures

 

Notwithstanding anything else contained in
this Plan, the Company may, from time to time, implement such procedures and conditions as it determines appropriate with respect
to the withholding and remittance of taxes imposed under applicable law, or the funding of related amounts for which liability
may arise under such applicable law. Without limiting the generality of the foregoing, an Optionee who wishes to exercise an Option
must, in addition to following the procedures set out in this Article 4 and elsewhere in this Plan, and as a condition of exercise:

 

		(a)	deliver a certified cheque, wire transfer or bank draft payable to the Company for the amount determined
by the Company to be the appropriate amount on account of such taxes or related amounts; or

 

		(b)	otherwise ensure, in a manner acceptable to the Company (if at all) in its sole and unfettered
discretion, that the amount will be securely funded; or

 

		(c)	direct a portion of the Common Shares acquired to be sold by a broker, the funds from such sale
paid to the Company and the Company directed to remit the funds received to the Canada Revenue Agency and/or such other applicable
provincial taxation authority in satisfaction of the applicable withholding requirements;

 

and must in all other respects follow any related procedures and
conditions imposed by the Company.

 

    - 14 -

     

    

 

ARTICLE 5 

TSX PROVISIONS

 

		5.1	Application

 

This Article 5 shall apply upon the date of
the listing of the Common Shares on the Toronto Stock Exchange and shall remain in force until such time as the Common Shares cease
to be listed for trading on the Toronto Stock Exchange. While this Article 5 applies, in the event of any conflict between this
Article 5 and any terms contained in any other Article of this Plan, this Article 5 shall govern. Upon the listing of the Common
Shares on the TSX and the de-listing of the Common Shares from the TSX- V, the Company shall be subject to the policies of the
TSX and will no longer be subject to the policies of the TSX-V.

 

		5.2	Definitions

 

Notwithstanding the definitions contained in
Section 1.1, the following terms shall have the meanings given to them below:

 

		(a)	“Affiliate” has the meaning given to such term in the TSX Company Manual;

 

		(b)	“Blackout Period” means an interval of time during which the Company has determined
that one or more Participants may not trade any securities of the Company because they may be in possession of undisclosed material
information pertaining to the Company, or when in anticipation of the release of quarterly or annual financials, to avoid potential
conflicts associated with a company’s insider-trading policy or applicable securities legislation, (which, for greater certainty,
does not include the period during which a cease trade order is in effect to which the Company or in respect of an Insider, that
Insider, is subject);

 

		(c)	“Disinterested Shareholder Approval” means approval of this Plan by a majority
of the Company’s security holders, in accordance with the requirements stipulated in the TSX Company Manual, which for greater
certainty, excludes the votes cast by Insiders entitled to receive a benefit under this Plan;

 

		(d)	“Effective Date” for an Option means the date of grant thereof by the Board;

 

		(e)	“Eligible Participant” means any Person who is a bona fide Director,
Officer, Employee or Consultant and also includes a company, 100% of the share capital of which is beneficially owned by one or
more Eligible Participants;

 

		(f)	“Insider” means an insider as defined in the TSX Company Manual which, as at
the date hereof, means an insider as defined in the Securities Act (Ontario), which as at the date hereof, among other things,
includes (i) a director or officer of a reporting issuer; (ii) a director or officer of a person or company that is itself an insider
or subsidiary of a reporting issuer; and (iii) a person or company that has either individually or in the aggregate beneficial
ownership of, or control or direction over, directly or indirectly, securities of a reporting issuer carrying more than 10% of
the voting rights attached to all of the reporting issuer’s outstanding voting securities, excluding, for the purpose of
the calculation of the percentage held, any securities held by the person or company as underwriter in the course of a distribution;

 

    - 15 -

     

    

 

		(g)	“Insider Participation Limit” means the insider participation limit as defined
in the TSX Company Manual, which, as at the date hereof, means the number of the Company’s Common Shares: (i) issued to Insiders
within any one year period, and (ii) issuable to Insiders, at any time, under this Plan, or when combined with all of the Company’s
other security based compensation arrangements, which cannot exceed 10% of the Company’s total issued and outstanding securities,
respectively;

 

		(h)	“Market Price” has the meaning given to such term in the TSX Company Manual;

 

		(i)	“Option” means the right to purchase Common Shares granted hereunder to an Eligible
Participant;

 

		(j)	“Participant” means an Eligible Participant that becomes an Optionee;

 

		(k)	“TSX” means the Toronto Stock Exchange and any successor thereto; and

 

		(l)	“TSX Company Manual” means the rules and policies of the TSX contained in the
TSX Company Manual, as amended from time to time.

 

		5.3	Eligibility 

 

Notwithstanding the restrictions contained in Section 2.2 hereof,
Options to purchase Common Shares may be granted hereunder to Eligible Participants, from time to time by the Board.

 

		5.4	Limitations on Issue

 

Subject to Section 5.7 hereof:

 

		(a)	an Eligible Participant cannot be granted an Option that would exceed the Insider Participation Limit; and

 

		(b)	the aggregate number of Options granted to all Insiders cannot exceed the Insider Participation Limit;

 

unless, in either case, the Company has obtained Disinterested
Shareholder Approval to do so in accordance with the TSX Company Manual.

 

		5.5	Number of Common Shares

 

Notwithstanding Section 3.2 hereof and subject to adjustment as
provided for in Section 3.10 hereof:

 

		(a)	the maximum number of Common Shares that may be reserved and available for issuance upon exercise
of Options shall be the greater of:

 

		(A)	3,614,014 Common Shares; and

 

		(B)	a rolling number equal to 15% of the total issued and outstanding Common Shares from time to time,
subject to a maximum of 5,000,000 Common Shares;

 

    - 16 -

     

    

 

		(b)	the maximum number of Common Shares that may be reserved and available for issuance under Section
5.5(a)(B) above will be increased quarterly at the end of each fiscal quarter of the Company beginning with the fiscal quarter
beginning on April 1, 2015 by an amount equal to the number of Common Shares issued upon exercise of any Options during such fiscal
quarter, provided that the total number of Common Shares reserved and available for issuance does not exceed 15% of the issued
and outstanding Common Shares of the Company; and

 

		(c)	any Common Shares subject to an Option that expires or terminates without having been fully exercised
may be made the subject of a further Option.

 

		5.6	Amendment to Plan or Options by the Board 

 

Notwithstanding Section 7.1 hereof, and subject
to the requirements of the TSX Company Manual and Section 5.7 hereof, the Board will have the right at any time and from time to
time, to amend any of the provisions of this Plan or any Option in any manner without consent or approval from any Participant
or shareholder of the Company (provided that no such amendment may be made that will materially prejudice the rights of any Participant
under any Option previously granted to the Participant without consent by such Participant), including without limitation:

 

		(a)	to amend, modify or terminate this Plan with respect to all Common Shares in respect of Options
which have not yet been granted hereunder;

 

		(b)	to make any amendment of a typographical, grammatical, clerical or administrative nature or clarification
correcting or rectifying any ambiguity, immaterial inconsistency, defective provision, mistake, or error or omission in this Plan
or any Option;

 

		(c)	to change the provisions relating to the manner of exercise of Options, including changing or adding
any form of financial assistance provided by the Company, or if this Plan has a fixed number of securities issuable, adding or
amending provisions relating to a cashless exercise of Options which provisions so added or amended provide for a full deduction
of the underlying Common Shares from the maximum number reserved for issuance under this Plan;

 

		(d)	to change the terms, conditions and mechanics of grant, vesting, exercise and early expiry of Options,
provided that no such change may extend an outstanding Option Certificate’s Expiry Date;

 

		(e)	to change the provisions for termination or cancellation of Options, or to extend an outstanding
Option Certificate’s Expiry Date; and

 

		(f)	to make any addition to, deletion from or alteration of the provisions of this Plan or any Option
that are necessary to comply with applicable law or the requirements of any regulatory or governmental agency or applicable stock
exchange and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of this Plan.

 

    - 17 -

     

    

 

		5.7	Amendments Requiring Disinterested Shareholder Approval 

 

Notwithstanding Section 5.6 and Section 7.1 hereof, the Company
will be required to obtain Disinterested Shareholder Approval prior to any of the following actions becoming effective:

 

		(a)	any reduction in the Exercise Price of an Option previously granted to an Insider;

 

		(b)	any extension of the Expiry Date of an Option previously granted to an Insider;

 

		(c)	any amendment to remove or to exceed the Insider Participation Limit;

 

		(d)	any increase in the maximum number of securities issuable under this Plan, either as a fixed number
or a fixed percentage of the Company’s issued and outstanding Common Shares; and

 

		(e)	any amendment to Section 5.6 hereof;

 

provided that Disinterested Shareholder
Approval will not be required for increases or decreases or substitution or adjustment to the number or kind of shares or other
securities reserved for issuance pursuant to this Plan or the number and kind of shares subject to unexercised Options granted
and in the Exercise Price of such Options and the making of provisions for the protection of the rights of Participants under this
Plan in accordance with the section or sections of this Plan which provide for such increase, decrease, substitution, adjustments
or provisions in respect of certain events, including any change in the outstanding Common Shares by reason of any stock dividend
or any recapitalization, amalgamation, subdivision, consolidation, combination or exchange or shares, other corporate change or
reorganization, amalgamation or consolidation of the Company, or for the amendment of such section or sections.

 

		5.8	Net Settlement

 

In lieu of exercising
the Option by delivery of the Exercise Notice along with payment of the Exercise Price as provided in Section 5.8
hereof, with the prior written approval of the Company, which may be granted or withheld in its sole discretion, any Optionee or
the Personal Representative of such Optionee may elect to transfer and dispose of a specified number of Options to the Company
in exchange for a number of Common Shares having a fair market value equal to the intrinsic value of such Options disposed of and
transferred to the Company (“Net Settlement”) by completing the Notice of Net Settlement set out as Schedule
C. The decision of whether or not to permit Net Settlement for any Option is in the sole discretion of the Company and will be
made on a case by case basis. Upon the Net Settlement of Options (the “Disposed Options”), the Company shall
deliver to the Optionee, that number of fully paid and non-assessable Common Shares (“X”) equal to the number of Disposed
Options (“Y”) multiplied by the quotient obtained by dividing the result of the Market Price of one Common Share (“B”)
less the Exercise Price per Common Share (“A”) by the Market Price of one Common Share (“B”). Expressed
as a formula, such number of Common Shares shall be computed as follows:

 

	 	X = (Y) x	(B - A)	 
	 	 	(B)	 

 

No fractional Common Shares shall be issuable
upon the Net Settlement of Options, such Common Shares to be rounded down to the nearest whole number.

 

    - 18 -

     

    

 

		5.9	Plan Subject to TSX Policies

 

The provisions of this Plan are subject to
the relevant policies of the TSX, including but not limited to the TSX Company Manual.

 

ARTICLE 6

ADMINISTRATION

 

		6.1	Administration

 

The Plan will be administered by the Administrator
on the instructions of the Board. The Board may make, amend and repeal at any time and from time to time such policies not inconsistent
with the Plan as it may deem necessary or advisable for the proper administration and operation of the Plan and such policies will
form part of the Plan. The Board may delegate to the Administrator or any director, officer or employee of the Company such administrative
duties and powers as it may see fit.

 

		6.2	Interpretation

 

The interpretation by the Board of any of the
provisions of the Plan and any determination by it pursuant thereto will be final and conclusive and will not be subject to any
dispute by any Optionee. No member of the Board or any person acting pursuant to authority delegated by it hereunder will be liable
for any action or determination in connection with the Plan made or taken in good faith and each member of the Board and each such
person will be entitled to indemnification with respect to any such action or determination in the manner provided for by the Company.

 

ARTICLE 7

AMENDMENT, TERMINATION AND NOTICE

 

		7.1	Termination and Amendment of Plan

 

Subject to Article 5:

 

		(a)	Power of the Board to Terminate or Amend Plan - Subject to the acceptance of
                                                               the applicable Regulatory Authorities, the Board may terminate, suspend or amend the terms of the Plan; provided, however,
                                                               that, except as provided in Section 4.1 hereof, the Board may not do any of the following without obtaining, within 12 months
                                                               either before or after the Board’s adoption of a resolution authorizing such action, approval by the affirmative votes
                                                               of the holders of a majority of the voting securities of the Company present, or represented, and entitled to vote at a
                                                               meeting duly held in accordance with the applicable corporate laws, and, where required, by way of Disinterested Shareholder
                                                               Approval, or by the written consent of the holders of a majority of the securities of the Company entitled to vote:

 

		(i)	reduce the exercise price of Options granted to Insiders, if the holder of such Options is an Insider
of the Company at the time of such proposed amendment;

 

		(ii)	grant to Insiders, within a 12 month period, number of options exceeding 10% of the Company’s
issued Common Shares;

 

		(iii)	issue to any one Optionee, within a 12 month period, a number of Common Shares exceeding 5% of
the Company’s Common Shares;

 

    - 19 -

     

    

 

		(iv)	reserve for issuance Common Shares under the Plan where such reservation could result in the number
of Common Shares granted to Insiders exceeding 10% of the Company’s issued Common Shares;

 

		(v)	materially modify the requirements as to eligibility for participation in the Plan;

 

		(vi)	materially increase the benefits accruing to participants under the Plan; or

 

		(vii)	modify the provisions of this Section 7.1,

 

however, the Board may amend the terms
of the Plan to comply with the requirements of any applicable Regulatory Authority, or as a result in the changes in Exchange policies
relating to incentive stock options, without obtaining the approval of the Company’s shareholders.

 

		(b)	No Grant During Suspension of Plan - No Option may be granted during any
                                                                   suspension, or after termination, of the Plan. Amendment, suspension or termination of the Plan shall not, without the
                                                                   consent of the Optionee, alter or impair any rights or obligations under any Option previously granted.

 

		7.2	Approvals 

 

The Plan and any amendments hereto are subject
to all necessary approvals of the applicable Regulatory Authorities.

 

		7.3	Termination

 

The Board may terminate the Plan at any time
provided that such termination will not alter the terms or conditions of any Option or impair any right of any Optionee pursuant
to any Option awarded prior to the date of such termination which will continue to be governed by the provisions of the Plan.

 

		7.4	Agreement

 

The Company and every Option awarded hereunder
will be bound by and subject to the terms and conditions of the Plan. By accepting an Option granted hereunder, the Optionee has
expressly agreed with the Company to be bound by the terms and conditions of the Plan.

 

		7.5	Notice

 

Any notice or other communication contemplated
under the Plan to be given by the Company to an Optionee will be given by the Company delivering or faxing the notice to the Optionee
at the last address for the Optionee in the Company’s records. Any such notice will be deemed to have been given on the date
on which it was delivered, or in the case of fax, the next business day after transmission. An Optionee may, at any time, advise
the Company of a change in the Optionee’s address or fax number.

 

    - 20 -

     

    

 

Schedule A

 

ESSA PHARMA INC. 

STOCK OPTION PLAN 

OPTION CERTIFICATE

 

This
Certificate is issued pursuant to the provisions of the ESSA Pharma Inc. (the “Company”) stock option plan (the
“Plan”) and evidences that ·
is the holder (the “Optionee”) of an option (the “Option”) to purchase up to ·
Common Shares Without Par Value (the “Common Shares”) in the capital stock of the Company. The Exercise Price
of the Option is Cdn. $·
per Common Share.

 

Subject to the provisions of the Plan:

 

		(a)	the Award Date of the Option is ·,
·;

 

		(b)	the Expiry Date of the Option is ·,
·;
and 

 

		(c)	the Option shall vest in accordance with the following schedule:

 

		(i)	·;
and 

 

		(ii)	·.

 

The vested portion or portions of the Option
may be exercised at any time and from time to time from and including the Award Date through to 5:00 p.m. local time in Vancouver,
British Columbia on the Expiry Date by delivering to the Administrator of the Plan an Exercise Notice, in the form provided in
the Plan, together with this Certificate and a certified cheque or bank draft payable to “ESSA Pharma Inc.” in an amount
equal to the aggregate of the Exercise Price of the Common Shares in respect of which the Option is being exercised.

 

This Certificate and the Option evidenced hereby
are not assignable, transferable or negotiable and are subject to the detailed terms and conditions contained in the Plan, the
terms and conditions of which the Optionee hereby expressly agrees with the Company to be bound by. This Certificate is issued
for convenience only and in the case of any dispute with regard to any matter in respect hereof, the provisions of the Plan and
the records of the Company will prevail.

 

The Option is also subject to the terms and
conditions contained in the schedules, if any, attached hereto. All terms not otherwise defined in this Certificate will have the
meanings given to them under the Plan.

 

Dated this
·
day of ·,
·.

 

ESSA PHARMA INC.

 

	Per:	 	 
	 	Administrator, Stock Option Plan	 
	 	ESSA Pharma Inc.	 

 

    - A-1 -

     

    

 

ESSA PHARMA INC.

OPTION CERTIFICATE – SCHEDULE

 

The additional terms and conditions attached to the Option represented
by this Certificate are as follows:

 

		1.	[NTD: Include any specialized terms desired.]

 

ESSA PHARMA INC.

 

	Per:	 	 
	 	Administrator, Stock Option Plan	 
	 	ESSA Pharma Inc.	 

 

    - A-2 -

     

    

 

Schedule B

 

ESSA PHARMA INC. 

STOCK OPTION PLAN 

NOTICE OF EXERCISE OF OPTION

 

	TO:	The Administrator, Stock Option Plan
	 	ESSA Pharma Inc.
	 	999 West Broadway Suite 720
	 	Vancouver, British Columbia V5Z 1K5

 

The undersigned hereby irrevocably gives notice,
pursuant to the ESSA Pharma Inc. stock option plan (the “Plan”), of the exercise of the Option to acquire and
hereby subscribes for (cross out inapplicable item):

 

		(a)	all of the Common Shares; or

 

		(b)	___________________ of the Common Shares,

 

which are the subject of the Option Certificate attached hereto.

 

The undersigned tenders herewith a certified
cheque or bank draft (circle one) payable to “ESSA Pharma Inc.” in an amount equal to the aggregate Exercise
Price of the aforesaid Common Shares and directs the Company to issue the certificate evidencing said Common Shares in the
name of the undersigned to be mailed to the undersigned at the following address:

 

___________________________________

 

___________________________________

 

___________________________________

 

By executing this Notice of Exercise of Option
the undersigned hereby confirms that the undersigned has read the Plan and agrees to be bound by the provisions of the Plan. All
terms not otherwise defined in this Notice of Exercise of Option will have the meanings given to them under the Option Certificate.

 

DATED the ________ day of ____________________, __________.

 

	 	 
	Signature of Optionee	 

 

    - B-1 -

     

    

 

Schedule C

 

STOCK OPTION PLAN 

NOTICE OF NET SETTLEMENT

 

	TO:	The Administrator, Stock Option Plan
	 	ESSA Pharma Inc.
	 	999 West Broadway Suite 720
	 	Vancouver, British Columbia V5Z 1K5

 

The undersigned
hereby requests, pursuant to the ESSA Pharma Inc. (the “Company”) stock option plan (the “Plan”),
the Company accept the transfer, disposition and surrender of the right to exercise ______________ Options in exchange for, subject
to the terms of the Plan and the Options, the number of Common Shares representing the fair market value of the Options disposed
of and transferred to the Company pursuant to the net settlement provisions set out in section 5.8 of the Plan (the “Net
Settlement Provisions”).

 

The undersigned, subject to the terms
of the Plan and the Options, is requesting to receive the fair market value of the Options in Common Shares pursuant to the Net
Settlement Provisions.

 

The undersigned directs the Company
to issue the certificate evidencing said Common Shares in the name of the undersigned to be mailed to the undersigned at the following
address:

 

___________________________________

 

___________________________________

 

___________________________________

 

By executing this Notice of Net Settlement
the undersigned hereby confirms that the undersigned has read the Plan and agrees to be bound by the provisions of the Plan. All
terms not otherwise defined in this Notice of Net Settlement will have the meanings given to them under the Option Certificate.

 

DATED the ____ day of ____________, 20__.

 

 

	 	 	 	 
	Signature of Witness	 	Signature of Participant	 
	 	 	 	 
	 	 	 	 
	Name of Witness (please print)	 	Name of Participant (please print)	 

 

    - C-1 -Exhibit 10.1

 

TROVAGENE, INC.

 

INDEMNIFICATION AGREEMENT

 

This INDEMNIFICATION AGREEMENT (“Agreement”) is made as of                  , 20   by and between Trovagene, Inc., a Delaware corporation (the “Company”), and                           (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.

 

RECITALS

 

WHEREAS, highly competent persons have become more reluctant to serve publicly held corporations as directors or officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation;

 

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company from certain liabilities. The By-Laws (the “By-Laws”) of the Company and the Certificate of Incorporation of the Company (“the Certificate of Incorporation”) require indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the “DGCL”). The By-Laws and the Certificate of Incorporation and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification;

 

WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;

 

WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company and its stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;

 

WHEREAS, it is reasonable, prudent and necessary for the Company to contractually obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified;

 

WHEREAS, this Agreement is a supplement to and in furtherance of the By-Laws and the Certificate of Incorporation and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder;

 

WHEREAS, Indemnitee does not regard the protection available under the By-Laws and insurance as adequate in the present circumstances, and may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he be so indemnified; and

 

1

 

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:

 

Section 1.  Services to the Company.  Indemnitee agrees to [continue to] serve as a [director] [officer] [employee] [agent] of the Company. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to keep Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company and Indemnitee. Indemnitee specifically acknowledges that Indemnitee’s employment with the Company, if any, is at will, and the Indemnitee may be discharged at any time for any reason, with or without cause, except as may be otherwise provided in any written employment contract between Indemnitee and the Company, other applicable formal severance policies duly adopted by the Board, or, with respect to service as a director or officer of the Company, by the Certificate of Incorporation, the By-Laws, and the DGCL. The foregoing notwithstanding, this Agreement shall continue in force after Indemnitee has ceased to serve as an [officer] [director] [employee] [agent] of the Company.

 

Section 2.  Definitions.  As used in this Agreement:

 

(a)         References to “agent” shall mean any person who is or was a director, officer, or employee of the Company or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a director, officer, employee, fiduciary or other official of another corporation, partnership, limited liability company, joint venture, trust or other Enterprise at the request of, for the convenience of, or to represent the interests of the Company.

 

(b)         A “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:

 

(i)                         Acquisition of Stock by Third Party.  Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing more than fifty percent (50%) or more of the combined voting power of the Company’s then outstanding securities;

 

(ii)                      Change in Board.  During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 2(b)(i), 2(b)(iii) or 2(b)(iv)) whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board;

 

(iii)                   Corporate Transactions.  The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 51% of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity;

 

(iv)                  Liquidation.  The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets; and

 

2

 

(v)                     Other Events.  There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement.

 

For purposes of this Section 2(b), the following terms shall have the following meanings:

 

(A)       “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time.

 

(B)       “Person” shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act; provided, however, that Person shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.

 

(C)       “Beneficial Owner” shall have the meaning given to such term in Rule 13d-3 under the Exchange Act; provided, however, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the Company with another entity.

 

(c)          “Corporate Status” describes the status of a person who is or was a director, officer, employee or agent of the Company or of any other corporation, limited liability company, partnership or joint venture, trust, employee benefit plan or other enterprise which such person is or was serving at the request of the Company.

 

(d)         “Disinterested Director” means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.

 

(e)          “Enterprise” shall mean the Company and any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, employee, agent or fiduciary.

 

(f)           “Expenses” shall include all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, ERISA excise taxes and penalties, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also shall include (i) Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond or other appeal bond or its equivalent, and (ii) for purposes of Section 14(d) only, Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee’s rights under this Agreement, by litigation or otherwise. The parties agree that for the purposes of any advancement of Expenses for which Indemnitee has made written demand to the Company in accordance with this Agreement, all Expenses included in such demand that are certified by affidavit of Indemnitee’s counsel as being reasonable shall be presumed conclusively to be reasonable. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.

 

(g)          “Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for

 

3

 

indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

 

(h)         The term “Proceeding” shall include any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative legislative, or investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is or will be involved as a party, potential party, non-party witness or otherwise by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action taken by him or of any action on his part while acting as director or officer of the Company, or by reason of the fact that he is or was serving at the request of the Company, including prior to the date of this Agreement, as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust or other enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement, or advancement of expenses can be provided under this Agreement. If the Indemnitee believes in good faith that a given situation may lead to or culminate in the institution of a Proceeding, this shall be considered a Proceeding under this paragraph.

 

(i)             Reference to “other enterprise” shall include employee benefit plans; references to “fines” shall include any excise tax assessed with respect to any employee benefit plan; references to “serving at the request of the Company” shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner he reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement.

 

Section 3.  Indemnity in Third-Party Proceedings.  The Company shall indemnify Indemnitee in accordance with the provisions of this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding had no reasonable cause to believe that his conduct was unlawful. The parties hereto intend that this Agreement shall provide to the fullest extent permitted by law for indemnification in excess of that expressly permitted by statute, including, without limitation, any indemnification provided by the Certificate of Incorporation, the By-Laws, vote of the Company’s stockholders or disinterested directors or applicable law.

 

Section 4.  Indemnity in Proceedings by or in the Right of the Company.  The Company shall indemnify Indemnitee in accordance with the provisions of this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 4, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by him or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith

 

4

 

and in a manner he reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification.

 

Section 5.  Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provisions of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with or related to each successfully resolved claim, issue or matter to the fullest extent permitted by law. For purposes of this Section 5 and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

 

Section 6.  Indemnification For Expenses of a Witness.  Notwithstanding any other provision of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is, by reason of his Corporate Status, a witness or otherwise asked to participate in any Proceeding to which Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith.

 

Section 7.  Partial Indemnification.  If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of Expenses, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled.

 

Section 8.  Additional Indemnification.

 

(a)         Notwithstanding any limitation in Sections 3, 4, or 5, the Company shall indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee in connection with the Proceeding.

 

(b)         For purposes of Section 8(a), the meaning of the phrase “to the fullest extent permitted by applicable law” shall include, but not be limited to:

 

(i)                         to the fullest extent permitted by the provision of the DGCL that authorizes or contemplates additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL, and

 

(ii)                      to the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors.

 

Section 9.  Exclusions.  Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection with any claim made against Indemnitee:

 

5

 

(a)         for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or

 

(b)         for (i) an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act (as defined in Section 2(b) hereof) or similar provisions of state statutory law or common law, or (ii) any reimbursement of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act); or

 

(c)          except as provided in Section 14(d) of this Agreement, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law.

 

Section 10.  Advances of Expenses.  In accordance with Section 3 of Article XI of the By-Laws, and notwithstanding any provision of this Agreement to the contrary, the Company shall advance, to the extent not prohibited by law, the Expenses incurred by Indemnitee in connection with any Proceeding, and such advancement shall be made within thirty (30) days after the receipt by the Company of a statement or statements requesting such advances from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee’s ability to repay the Expenses and without regard to Indemnitee’s ultimate entitlement to indemnification under the other provisions of this Agreement. Advances shall include any and all reasonable Expenses incurred pursuing an action to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed. The Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement, which shall constitute an undertaking providing that the Indemnitee undertakes to repay the amounts advanced (without interest) to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company. No other form of undertaking shall be required other than the execution of this Agreement. This Section 10 shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section 9.

 

Section 11.  Procedure for Notification and Defense of Claim.

 

(a)         Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. The written notification to the Company shall include a description of the nature of the Proceeding and the facts underlying the Proceeding. To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of such action, suit or proceeding. The omission by Indemnitee to notify the Company hereunder will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights under this Agreement.

 

6

 

The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification.

 

(b)         The Company will be entitled to participate in the Proceeding at its own expense.

 

Section 12.  Procedure Upon Application for Indemnification.

 

(a)         Upon written request by Indemnitee for indemnification pursuant to Section 11(a), a determination, if required by applicable law, with respect to Indemnitee’s entitlement thereto shall be made in the specific case: (i) if a Change in Control shall have occurred, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee; or (ii) if a Change in Control shall not have occurred, (A) by a majority vote of the Disinterested Directors, even if less than a quorum of the Board, (B) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even if less than a quorum of the Board, (C) if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee or (D) if so directed by the Board, by the stockholders of the Company; and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination. Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or Expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.

 

(b)         In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a) hereof, the Independent Counsel shall be selected as provided in this Section 12(b). If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Board, and the Company shall give written notice to Indemnitee advising him of the identity of the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within twenty (20) days after the later of submission by Indemnitee of a written request for indemnification pursuant to Section 11(a) hereof and the final disposition of the Proceeding, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition a court of competent jurisdiction for resolution of any objection which shall have been made by the Company or Indemnitee to the other’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the Court or by such other person as the Court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 12(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 14(a) of this Agreement, Independent Counsel

 

7

 

shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).

 

Section 13.  Presumptions and Effect of Certain Proceedings.

 

(a)         In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 11(a) of this Agreement, and the Company shall, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption. Neither the failure of the Company (including by its directors or independent legal counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or independent legal counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.

 

(b)         Subject to Section 14(e), if the person, persons or entity empowered or selected under Section 12 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall, to the fullest extent not prohibited by law, be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this Section 13(b) shall not apply (i) if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 12(a) of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination the Board has resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat, or (ii) if the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a) of this Agreement.

 

(c)          The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was unlawful.

 

(d)         Reliance as Safe Harbor. For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with the reasonable care by the Enterprise. The

 

8

 

provisions of this Section 13(d) shall not be deemed to be exclusive or to limit in any way the other circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.

 

(e)          Actions of Others. The knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.

 

Section 14.  Remedies of Indemnitee.

 

(a)         Subject to Section 14(e), in the event that (i) a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 10 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 12(a) of this Agreement within ninety (90) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Section 5, 6 or 7 or the last sentence of Section 12(a) of this Agreement within ten (10) days after receipt by the Company of a written request therefor, (v) payment of indemnification pursuant to Section 3, 4 or 8 of this Agreement is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, or (vi) in the event that the Company or any other person takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or Proceeding designed to deny, or to recover from, the Indemnitee the benefits provided or intended to be provided to the Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by a court of his entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 14(a); provided, however, that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce his rights under Section 5 of this Agreement. The Company shall not oppose Indemnitee’s right to seek any such adjudication or award in arbitration.

 

(b)         In the event that a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 14 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 14 the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.

 

(c)          If a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 14, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.

 

(d)         The Company shall, to the fullest extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. It is the intent of the Company that, to the fullest extent permitted by law, the Indemnitee not be required to incur legal fees or other Expenses associated with the interpretation, enforcement or defense of

 

9

 

Indemnitee’s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to the Indemnitee hereunder. The Company shall, to the fullest extent permitted by law, indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advancement of Expenses from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company if Indemnitee is wholly successful on the underlying claims; if Indemnitee is not wholly successful on the underlying claims, then such indemnification and advancement shall be only to the extent Indemnitee is successful on such underlying claims or otherwise as permitted by law, whichever is greater.

 

(e)          Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement of Indemnitee to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding.

 

Section 15.  Non-exclusivity; Survival of Rights; Insurance; Subrogation.

 

(a)         The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the By-Laws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the By-Laws, the Certificate of Incorporation and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.

 

(b)         The Company shall use its best efforts to maintain an insurance policy or policies providing liability insurance for directors and officers in effect at all times.  To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or agents of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, employee or agent under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such claim or of the commencement of a proceeding, as the case may be, to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.

 

(c)          In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

 

10

 

(d)         The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable (or for which advancement is provided hereunder) hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.

 

(e)          The Company’s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, employee or agent of any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses from such other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise.

 

Section 16.  Duration of Agreement.  This Agreement shall continue until and terminate upon the later of: (a) ten (10) years after the date that Indemnitee shall have ceased to serve as a [director] [officer] [employee] [agent] of the Company or (b) one (1) year after the final termination of any Proceeding then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section 14 of this Agreement relating thereto. This Agreement shall be binding upon the Company and its successors and assigns and shall inure to the benefit of Indemnitee and his heirs, executors and administrators.

 

Section 17.  Severability.  If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.

 

Section 18.  Enforcement.

 

(a)         The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company.

 

(b)         This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; provided, however, that this Agreement is a supplement to and in furtherance of the Certificate of Incorporation, the By-Laws and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.

 

Section 19.  Modification and Waiver.  No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the parties thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver.

 

11

 

Section 20.  Notice by Indemnitee.  Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement or otherwise.

 

Section 21.  Notices.  All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (a) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (c) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (d) sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received:

 

(i)                         If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide to the Company.

 

(ii)                      If to the Company to

 

Trovagene, Inc.

11055 Flintkote Avenue, Suite A

San Diego, CA 92121

Attention: President and Chief Executive Officer

 

or to any other address as may have been furnished to Indemnitee by the Company.

 

Section 22.  Contribution.  To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (a) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (b) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s).

 

Section 23.  Applicable Law and Consent to Jurisdiction.  This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 14(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (a) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court of the State of Delaware (the “Delaware Court”), and not in any other state or federal court in the United States of America or any court in any other country, (b) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (c) appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, irrevocably The Corporation Service Company, 2711 Centerville Road, City of Wilmington, County of New Castle, Delaware 19808 as its agent in the State of Delaware as such party’s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (d) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (e) waive, and agree not to plead or

 

12

 

to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.

 

Section 24.  Identical Counterparts.  This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

 

Section 25.  Miscellaneous.  Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The headings of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.

 

	
 
    	
TROVAGENE, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    
	
 
    	
Title:
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
INDEMNITEE
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Address:
    
	
 
    	
 
    
				

 

13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]